Pmg Nw Wa - Medicare Mental Health Clinic in Everett, WA

Pmg Nw Wa is a medicare enrolled mental health clinic (General Practice) in Everett, Washington. The current practice location for Pmg Nw Wa is 900 Pacific Ave, Ste 501, Everett, Washington. For appointments, you can reach them via phone at (425) 258-7550. The mailing address for Pmg Nw Wa is Po Box 3360, Portland, Oregon and phone number is (866) 366-2983.

Pmg Nw Wa is licensed to practice in * (Not Available) (license number ). The clinic also participates in the medicare program and its NPI number is 1124270715. This medical practice accepts medicare insurance (which means this clinic accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance). However, please confirm if they accept your insurance at (425) 258-7550.

Contact Information

Pmg Nw Wa
900 Pacific Ave
Ste 501
Everett
WA 98201-4168
(425) 258-7550
(425) 258-7450

Mental Health Clinic Profile

Full NamePmg Nw Wa
SpecialityGeneral Practice
Location900 Pacific Ave, Everett, Washington
Authorized Official Name and PositionDonald Wayne Anderson (ASSISTANT SECRETARY FOR ENROLLMENT)
Authorized Official Contact4255255392
Accepts Medicare InsuranceYes. This clinic participates in medicare program and accept medicare insurance.

Mailing Address and Practice Location

Mailing AddressPractice Location Address
Pmg Nw Wa
Po Box 3360
Portland
OR 97208-3360

Ph: (866) 366-2983
Pmg Nw Wa
900 Pacific Ave
Ste 501
Everett
WA 98201-4168

Ph: (425) 258-7550

NPI Details:

NPI Number1124270715
Provider Enumeration Date10/15/2008
Last Update Date08/15/2023
Certification Date08/15/2023

Medicare PECOS Information:

Medicare PECOS PAC ID8325100480
Medicare Enrollment IDO20081224000111

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Medical Identifiers

Medical identifiers for Pmg Nw Wa such as npi, medicare ID, medicare PIN, medicaid, etc.
IdentifierTypeStateIssuer
1124270715NPI-NPPES

Medical Taxonomies and Licenses

TaxonomyTypeLicense (State)Status
1041C0700XSocial Worker - Clinical (* (Not Available))Secondary
208D00000XGeneral Practice (* (Not Available))Primary
225100000XPhysical Therapist (* (Not Available))Secondary

Medicare Reassignments

Some practitioners may not bill the customers directly but medicare billing happens through clinics / group practice / hospitals where the provider works. Pmg Nw Wa acts as a billing entity for following providers:
Provider NameRavi S Singh
Provider TypePractitioner - Family Practice
Provider IdentifiersNPI Number: 1699757112
PECOS PAC ID: 2365356771
Enrollment ID: I20031118001005

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameTaehee Kim
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1528163615
PECOS PAC ID: 5193624807
Enrollment ID: I20031231000692

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameFa Abigail C De Imus
Provider TypePractitioner - Dermatology
Provider IdentifiersNPI Number: 1265498901
PECOS PAC ID: 3375443203
Enrollment ID: I20040108001120

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameSusan M Blue
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1265543839
PECOS PAC ID: 9234022476
Enrollment ID: I20040203000608

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameRobert D Defrang
Provider TypePractitioner - Vascular Surgery
Provider IdentifiersNPI Number: 1649257692
PECOS PAC ID: 7214823509
Enrollment ID: I20040224000854

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameGerardo R Rodriquez
Provider TypePractitioner - Emergency Medicine
Provider IdentifiersNPI Number: 1245299916
PECOS PAC ID: 8022000603
Enrollment ID: I20040401001678

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameLeah Ruth Lambert
Provider TypePractitioner - Certified Nurse Midwife (cnm)
Provider IdentifiersNPI Number: 1417049008
PECOS PAC ID: 7214922335
Enrollment ID: I20040419000296

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameDan S Veljovich
Provider TypePractitioner - Gynecological Oncology
Provider IdentifiersNPI Number: 1770535833
PECOS PAC ID: 9931196375
Enrollment ID: I20040428000644

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameOrly P Steinberg
Provider TypePractitioner - Obstetrics/gynecology
Provider IdentifiersNPI Number: 1407812506
PECOS PAC ID: 3072501089
Enrollment ID: I20040506000008

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameRobert J Golden
Provider TypePractitioner - Urology
Provider IdentifiersNPI Number: 1710988746
PECOS PAC ID: 8729077805
Enrollment ID: I20040512000761

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameVernetta M Stewart
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1033201512
PECOS PAC ID: 2062403579
Enrollment ID: I20040522000362

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameErin C Sutcliffe
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1689750309
PECOS PAC ID: 1759362700
Enrollment ID: I20040526000935

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJames B Erhardt
Provider TypePractitioner - Otolaryngology
Provider IdentifiersNPI Number: 1043251697
PECOS PAC ID: 1052208998
Enrollment ID: I20040602001299

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameEileen M Olinger
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1992806228
PECOS PAC ID: 4587648159
Enrollment ID: I20040614000672

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJudith H Kuo
Provider TypePractitioner - Pathology
Provider IdentifiersNPI Number: 1124129648
PECOS PAC ID: 5799761524
Enrollment ID: I20040624000755

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameKatie E Lee
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1194820290
PECOS PAC ID: 7618957697
Enrollment ID: I20040721000644

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameDaniel A. Wuthrich
Provider TypePractitioner - Cardiovascular Disease (cardiology)
Provider IdentifiersNPI Number: 1285696880
PECOS PAC ID: 6103806120
Enrollment ID: I20040721000937

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameMichelle M Housel
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1336236983
PECOS PAC ID: 2466423801
Enrollment ID: I20040802000333

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NamePaolo Rocca
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1356446934
PECOS PAC ID: 6800868381
Enrollment ID: I20040806000651

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameAngela H Chen
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1659445609
PECOS PAC ID: 2264346618
Enrollment ID: I20040814000138

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameKelly A Welz
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1699855544
PECOS PAC ID: 9537134069
Enrollment ID: I20040830000102

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameBrian C Fong
Provider TypePractitioner - Urology
Provider IdentifiersNPI Number: 1407888910
PECOS PAC ID: 5991770349
Enrollment ID: I20040830000227

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameAine Kelly Yore
Provider TypePractitioner - Emergency Medicine
Provider IdentifiersNPI Number: 1205885373
PECOS PAC ID: 4789666132
Enrollment ID: I20041110001124

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameDamanjeet S Chugh
Provider TypePractitioner - Hospitalist
Provider IdentifiersNPI Number: 1366492944
PECOS PAC ID: 8224092473
Enrollment ID: I20041117000261

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameAhmet C Tural
Provider TypePractitioner - Infectious Disease
Provider IdentifiersNPI Number: 1205927035
PECOS PAC ID: 5799741419
Enrollment ID: I20041204000255

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJoseph J Austin
Provider TypePractitioner - Other (physician)
Provider IdentifiersNPI Number: 1134189699
PECOS PAC ID: 6406812957
Enrollment ID: I20041206001190

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJeffrey D Ries
Provider TypePractitioner - Emergency Medicine
Provider IdentifiersNPI Number: 1780609743
PECOS PAC ID: 5597722678
Enrollment ID: I20041210000546

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameWilliam A Peters
Provider TypePractitioner - Gynecological Oncology
Provider IdentifiersNPI Number: 1063449940
PECOS PAC ID: 6507754546
Enrollment ID: I20050114000830

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameCharles W Drescher
Provider TypePractitioner - Gynecological Oncology
Provider IdentifiersNPI Number: 1710939855
PECOS PAC ID: 7719936814
Enrollment ID: I20050114000862

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameRoy Hanaki
Provider TypePractitioner - Emergency Medicine
Provider IdentifiersNPI Number: 1487684254
PECOS PAC ID: 8820996234
Enrollment ID: I20050125000245

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NamePatricia L Rolstad
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1043279623
PECOS PAC ID: 1153374756
Enrollment ID: I20050223000606

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameBrandon N Ong
Provider TypePractitioner - Hospitalist
Provider IdentifiersNPI Number: 1013968072
PECOS PAC ID: 2466405535
Enrollment ID: I20050301000473

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameEric K Lee
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1659476760
PECOS PAC ID: 6800833963
Enrollment ID: I20050411001245

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameKatherine D Bumstead
Provider TypePractitioner - Family Practice
Provider IdentifiersNPI Number: 1639270762
PECOS PAC ID: 7810934726
Enrollment ID: I20050412001335

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameShona E Lowell
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1598710840
PECOS PAC ID: 3779523162
Enrollment ID: I20050504001274

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameThomas M Richardson
Provider TypePractitioner - Cardiovascular Disease (cardiology)
Provider IdentifiersNPI Number: 1609817295
PECOS PAC ID: 9436191129
Enrollment ID: I20050523001341

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameDonald E Rice
Provider TypePractitioner - Psychiatry
Provider IdentifiersNPI Number: 1689683583
PECOS PAC ID: 7416990205
Enrollment ID: I20050603001053

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameSarah M Hansen
Provider TypePractitioner - Emergency Medicine
Provider IdentifiersNPI Number: 1619921970
PECOS PAC ID: 3678503893
Enrollment ID: I20050817000813

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameMark Papenhausen
Provider TypePractitioner - Vascular Surgery
Provider IdentifiersNPI Number: 1740268325
PECOS PAC ID: 6305837659
Enrollment ID: I20051006000598

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameRicardo W Rodriguez
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1992858377
PECOS PAC ID: 4082631809
Enrollment ID: I20051031000482

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameLloyd Andrew Roberts
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1235219205
PECOS PAC ID: 4486672821
Enrollment ID: I20051104000094

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameEdnea A Simon
Provider TypePractitioner - Neurology
Provider IdentifiersNPI Number: 1174604425
PECOS PAC ID: 9335160340
Enrollment ID: I20051216000671

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NamePatrick J Dabbracci
Provider TypePractitioner - Emergency Medicine
Provider IdentifiersNPI Number: 1902858913
PECOS PAC ID: 9537199047
Enrollment ID: I20060120000106

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameKathleen M Wroblewski
Provider TypePractitioner - Nephrology
Provider IdentifiersNPI Number: 1215033287
PECOS PAC ID: 7517973340
Enrollment ID: I20060302000314

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameSharon Vanover Wuerth
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1821072356
PECOS PAC ID: 1951318104
Enrollment ID: I20060313000352

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameAngela S Rideout
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1750423554
PECOS PAC ID: 1759398811
Enrollment ID: I20060315000568

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameWard K Chow
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1669430146
PECOS PAC ID: 2769418433
Enrollment ID: I20060407000611

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameHemalatha Subbaratnam
Provider TypePractitioner - Neurology
Provider IdentifiersNPI Number: 1588732036
PECOS PAC ID: 4183611072
Enrollment ID: I20060419000214

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameHarold F Andersen
Provider TypePractitioner - Obstetrics/gynecology
Provider IdentifiersNPI Number: 1346334489
PECOS PAC ID: 2365483757
Enrollment ID: I20060420000532

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameLaurel K Walker
Provider TypePractitioner - Qualified Audiologist
Provider IdentifiersNPI Number: 1801837406
PECOS PAC ID: 5193735991
Enrollment ID: I20060424000464

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameWilliam Berg
Provider TypePractitioner - Neurology
Provider IdentifiersNPI Number: 1568461507
PECOS PAC ID: 0143231548
Enrollment ID: I20060524000068

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameKimberly E Costas
Provider TypePractitioner - Thoracic Surgery
Provider IdentifiersNPI Number: 1922044973
PECOS PAC ID: 9931112059
Enrollment ID: I20060713000032

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameSteven A Grant
Provider TypePractitioner - Family Practice
Provider IdentifiersNPI Number: 1801831896
PECOS PAC ID: 2466465851
Enrollment ID: I20060802000181

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameStanley S Ling
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1457372294
PECOS PAC ID: 4284627001
Enrollment ID: I20060804000057

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NamePurnima Mahendra Patel
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1487619060
PECOS PAC ID: 8022921949
Enrollment ID: I20060906000069

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameEllen Mijung Kim
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1124024229
PECOS PAC ID: 5597666818
Enrollment ID: I20060906000099

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameTara E Nysoe
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1679597058
PECOS PAC ID: 0042215840
Enrollment ID: I20060929000380

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameTerri L Johnson
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1902826647
PECOS PAC ID: 9032184569
Enrollment ID: I20061005000138

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NamePeter D Sutcliffe
Provider TypePractitioner - Cardiovascular Disease (cardiology)
Provider IdentifiersNPI Number: 1699787028
PECOS PAC ID: 0244236248
Enrollment ID: I20061016000210

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameEmily M Savage
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1427084961
PECOS PAC ID: 5395741110
Enrollment ID: I20061018000182

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameArunachalam Einstein
Provider TypePractitioner - Emergency Medicine
Provider IdentifiersNPI Number: 1013943752
PECOS PAC ID: 3870518475
Enrollment ID: I20061102000598

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJohn Charles Lusk
Provider TypePractitioner - Emergency Medicine
Provider IdentifiersNPI Number: 1932208592
PECOS PAC ID: 0547268286
Enrollment ID: I20061113000544

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameGregory G Johnson
Provider TypePractitioner - Emergency Medicine
Provider IdentifiersNPI Number: 1093826406
PECOS PAC ID: 5799784443
Enrollment ID: I20061207000207

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJerry S Koh
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1881705200
PECOS PAC ID: 9234138207
Enrollment ID: I20061220000542

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameWendi D Alexander
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1689757874
PECOS PAC ID: 3274533914
Enrollment ID: I20070103000485

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameTodd M Denkinger
Provider TypePractitioner - Emergency Medicine
Provider IdentifiersNPI Number: 1689654212
PECOS PAC ID: 7214906528
Enrollment ID: I20070316000480

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameChristopher S Famy
Provider TypePractitioner - Psychiatry
Provider IdentifiersNPI Number: 1043329840
PECOS PAC ID: 7113023672
Enrollment ID: I20070501000159

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameBella Orbino
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1710199427
PECOS PAC ID: 4082713946
Enrollment ID: I20070619000377

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameRaymond Cheng
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1952469777
PECOS PAC ID: 8921107145
Enrollment ID: I20070628000204

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameMichael J Reznicek
Provider TypePractitioner - Psychiatry
Provider IdentifiersNPI Number: 1760568760
PECOS PAC ID: 0749389849
Enrollment ID: I20070629000304

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameAlbert D Pacifico
Provider TypePractitioner - Infectious Disease
Provider IdentifiersNPI Number: 1073519328
PECOS PAC ID: 4486754009
Enrollment ID: I20070712000054

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJamie M Crompton
Provider TypePractitioner - Certified Nurse Midwife (cnm)
Provider IdentifiersNPI Number: 1033292768
PECOS PAC ID: 4284726647
Enrollment ID: I20070815000701

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameLisa A Chiou
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1396850046
PECOS PAC ID: 4789776469
Enrollment ID: I20070827000205

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameMichael Y Wong
Provider TypePractitioner - Obstetrics/gynecology
Provider IdentifiersNPI Number: 1174535314
PECOS PAC ID: 8921190570
Enrollment ID: I20070827000863

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJasmine M Albrecht
Provider TypePractitioner - Obstetrics/gynecology
Provider IdentifiersNPI Number: 1972705762
PECOS PAC ID: 0547352197
Enrollment ID: I20070827000886

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameHunter A Mckay
Provider TypePractitioner - Urology
Provider IdentifiersNPI Number: 1033112107
PECOS PAC ID: 1759474802
Enrollment ID: I20070905000388

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameWendy L Mcgoodwin
Provider TypePractitioner - Hospice/palliative Care
Provider IdentifiersNPI Number: 1285743641
PECOS PAC ID: 0648363648
Enrollment ID: I20070907000156

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameSheila D Smith
Provider TypePractitioner - Neurology
Provider IdentifiersNPI Number: 1487859708
PECOS PAC ID: 7911090519
Enrollment ID: I20070912000164

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameKristy M Thompson
Provider TypePractitioner - Family Practice
Provider IdentifiersNPI Number: 1205020591
PECOS PAC ID: 6406940774
Enrollment ID: I20070917000708

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameSeunghyun Lee
Provider TypePractitioner - Physical Medicine And Rehabilitation
Provider IdentifiersNPI Number: 1356435184
PECOS PAC ID: 6002919636
Enrollment ID: I20070924000445

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameChad A Warren
Provider TypePractitioner - Orthopedic Surgery
Provider IdentifiersNPI Number: 1235244054
PECOS PAC ID: 8123098068
Enrollment ID: I20071005000078

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJames C Tsai
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1225149172
PECOS PAC ID: 0941392484
Enrollment ID: I20071015000469

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameSarah E Stolz
Provider TypePractitioner - Neurology
Provider IdentifiersNPI Number: 1053471425
PECOS PAC ID: 1850480138
Enrollment ID: I20071210000415

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NamePatris S Marandi
Provider TypePractitioner - General Surgery
Provider IdentifiersNPI Number: 1922055581
PECOS PAC ID: 1850472499
Enrollment ID: I20080121000332

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameArpan Waghray
Provider TypePractitioner - Psychiatry
Provider IdentifiersNPI Number: 1801088794
PECOS PAC ID: 5597847459
Enrollment ID: I20080130000729

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameRonald L Brown
Provider TypePractitioner - Emergency Medicine
Provider IdentifiersNPI Number: 1710932991
PECOS PAC ID: 0941254478
Enrollment ID: I20080205000679

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameGrace T Dy
Provider TypePractitioner - Emergency Medicine
Provider IdentifiersNPI Number: 1295792109
PECOS PAC ID: 6305928136
Enrollment ID: I20080211000792

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameLee Loung Liou
Provider TypePractitioner - Neurology
Provider IdentifiersNPI Number: 1013022151
PECOS PAC ID: 6002999216
Enrollment ID: I20080212000127

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameChristine M Perez
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1174637771
PECOS PAC ID: 1759465156
Enrollment ID: I20080225000090

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJohn Myunghoon Pyun
Provider TypePractitioner - Emergency Medicine
Provider IdentifiersNPI Number: 1073599866
PECOS PAC ID: 8426098955
Enrollment ID: I20080606000738

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NamePoonam Rauniyar
Provider TypePractitioner - Pediatric Medicine
Provider IdentifiersNPI Number: 1366602468
PECOS PAC ID: 7416029954
Enrollment ID: I20080628000073

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameMatthew J Beecroft
Provider TypePractitioner - Emergency Medicine
Provider IdentifiersNPI Number: 1487825782
PECOS PAC ID: 4587736541
Enrollment ID: I20080708000452

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameCynthia A Warner
Provider TypePractitioner - Cardiovascular Disease (cardiology)
Provider IdentifiersNPI Number: 1396906129
PECOS PAC ID: 9638242852
Enrollment ID: I20080722000369

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameErin M Robinson
Provider TypePractitioner - Qualified Audiologist
Provider IdentifiersNPI Number: 1437273034
PECOS PAC ID: 6103991690
Enrollment ID: I20080818000737

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameGregory M Pilmer
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1427162908
PECOS PAC ID: 3971678269
Enrollment ID: I20080821000181

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameYince N Loh
Provider TypePractitioner - Interventional Radiology
Provider IdentifiersNPI Number: 1720020894
PECOS PAC ID: 0547293417
Enrollment ID: I20080821000201

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameAshley B Johnson
Provider TypePractitioner - Emergency Medicine
Provider IdentifiersNPI Number: 1841360294
PECOS PAC ID: 5193761856
Enrollment ID: I20080821000619

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameAncuta Pandrea
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1285747188
PECOS PAC ID: 0941205850
Enrollment ID: I20080918000074

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameArwyn E Hood
Provider TypePractitioner - Emergency Medicine
Provider IdentifiersNPI Number: 1588714273
PECOS PAC ID: 5395814248
Enrollment ID: I20080925000714

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJeanine Ann Sommerville
Provider TypePractitioner - Family Practice
Provider IdentifiersNPI Number: 1669467304
PECOS PAC ID: 9931276045
Enrollment ID: I20081016000288

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameRajasri D Palepu
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1568644607
PECOS PAC ID: 5294893269
Enrollment ID: I20081020000369

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameKara Dacquisto
Provider TypePractitioner - Registered Dietitian Or Nutrition Professional
Provider IdentifiersNPI Number: 1912158239
PECOS PAC ID: 3274691753
Enrollment ID: I20081028000448

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameClinton W Anderson
Provider TypePractitioner - Family Practice
Provider IdentifiersNPI Number: 1134106867
PECOS PAC ID: 9436114477
Enrollment ID: I20081104000671

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameCatherine D Norton
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1013086495
PECOS PAC ID: 8729147699
Enrollment ID: I20081106000526

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameMonica Marton Popovici
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1437326626
PECOS PAC ID: 4385705763
Enrollment ID: I20081203000653

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameEvangeline C Gan
Provider TypePractitioner - Pediatric Medicine
Provider IdentifiersNPI Number: 1376644351
PECOS PAC ID: 7012070394
Enrollment ID: I20090113000361

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameRobert H Munoz
Provider TypePractitioner - Family Practice
Provider IdentifiersNPI Number: 1801997119
PECOS PAC ID: 6406919786
Enrollment ID: I20090113000423

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameBeena Morris
Provider TypePractitioner - Pediatric Medicine
Provider IdentifiersNPI Number: 1073614376
PECOS PAC ID: 9638232929
Enrollment ID: I20090113000479

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameRandall S Reimer
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1043311285
PECOS PAC ID: 7618030909
Enrollment ID: I20090113000496

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameIra Kantrowitz Gordon
Provider TypePractitioner - Certified Nurse Midwife (cnm)
Provider IdentifiersNPI Number: 1932292695
PECOS PAC ID: 9335202423
Enrollment ID: I20090115000659

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameLee R Argue
Provider TypePractitioner - Family Practice
Provider IdentifiersNPI Number: 1083714281
PECOS PAC ID: 3375606361
Enrollment ID: I20090119000017

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NamePatricia P Osetinsky
Provider TypePractitioner - Pediatric Medicine
Provider IdentifiersNPI Number: 1285735522
PECOS PAC ID: 4880757780
Enrollment ID: I20090120000018

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameTiffany Matteson
Provider TypePractitioner - Obstetrics/gynecology
Provider IdentifiersNPI Number: 1346331949
PECOS PAC ID: 8123181096
Enrollment ID: I20090120000673

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameCharles Blane Brinkley
Provider TypePractitioner - Obstetrics/gynecology
Provider IdentifiersNPI Number: 1710078399
PECOS PAC ID: 2668536293
Enrollment ID: I20090127000387

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameDeborah M Nalty
Provider TypePractitioner - Family Practice
Provider IdentifiersNPI Number: 1699876912
PECOS PAC ID: 6709940869
Enrollment ID: I20090204000402

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameManaji M Suzuki
Provider TypePractitioner - Pediatric Medicine
Provider IdentifiersNPI Number: 1154412955
PECOS PAC ID: 8820153802
Enrollment ID: I20090209000465

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameFred Martin Foss
Provider TypePractitioner - Urology
Provider IdentifiersNPI Number: 1437143179
PECOS PAC ID: 7416954797
Enrollment ID: I20090211000706

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameWendy Coffman
Provider TypePractitioner - Family Practice
Provider IdentifiersNPI Number: 1750482865
PECOS PAC ID: 1658436977
Enrollment ID: I20090219000356

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameMelissa Closs-brewer
Provider TypePractitioner - Pediatric Medicine
Provider IdentifiersNPI Number: 1467553529
PECOS PAC ID: 9436215506
Enrollment ID: I20090226000184

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameCelia Dastvan
Provider TypePractitioner - Pediatric Medicine
Provider IdentifiersNPI Number: 1346341377
PECOS PAC ID: 2668538745
Enrollment ID: I20090226000237

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameIgnatius Marsidi
Provider TypePractitioner - Gastroenterology
Provider IdentifiersNPI Number: 1396792149
PECOS PAC ID: 9234286956
Enrollment ID: I20090416000081

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameMichael J Doherty
Provider TypePractitioner - Neurology
Provider IdentifiersNPI Number: 1033299953
PECOS PAC ID: 5799833075
Enrollment ID: I20090423000797

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameGregg K Vandekieft
Provider TypePractitioner - Hospice/palliative Care
Provider IdentifiersNPI Number: 1922009885
PECOS PAC ID: 0749338333
Enrollment ID: I20090518000009

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameAmy E Bondurant
Provider TypePractitioner - Gynecological Oncology
Provider IdentifiersNPI Number: 1619992724
PECOS PAC ID: 3173526829
Enrollment ID: I20090518000117

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJeffrey R Scott
Provider TypePractitioner - Plastic And Reconstructive Surgery
Provider IdentifiersNPI Number: 1992814651
PECOS PAC ID: 4385794882
Enrollment ID: I20090603000606

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameChiyang Wu
Provider TypePractitioner - Family Practice
Provider IdentifiersNPI Number: 1760474738
PECOS PAC ID: 0941350755
Enrollment ID: I20090616000455

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameMichelle L Strong
Provider TypePractitioner - General Surgery
Provider IdentifiersNPI Number: 1285766121
PECOS PAC ID: 6608946025
Enrollment ID: I20090618000293

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameCatharine R Keay
Provider TypePractitioner - Emergency Medicine
Provider IdentifiersNPI Number: 1063624146
PECOS PAC ID: 1052460979
Enrollment ID: I20090630000092

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameWilliam Reed
Provider TypePractitioner - Thoracic Surgery
Provider IdentifiersNPI Number: 1891789582
PECOS PAC ID: 1658361910
Enrollment ID: I20090729000880

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameBhawna Gupta
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1649462102
PECOS PAC ID: 7214081165
Enrollment ID: I20090812000484

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameSuzanne K Bigelow
Provider TypePractitioner - Emergency Medicine
Provider IdentifiersNPI Number: 1679777213
PECOS PAC ID: 4284710591
Enrollment ID: I20090813000237

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameAlice B Brownstein
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1295811040
PECOS PAC ID: 2961556493
Enrollment ID: I20090819000130

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJenny B Hobbs
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1598874224
PECOS PAC ID: 9234284373
Enrollment ID: I20090826000228

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameLindsy J Alanis
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1003826603
PECOS PAC ID: 8820143498
Enrollment ID: I20090903000004

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameMegan A Farnsworth
Provider TypePractitioner - Emergency Medicine
Provider IdentifiersNPI Number: 1013159425
PECOS PAC ID: 9436201597
Enrollment ID: I20090910000415

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameGeetha Easwaran
Provider TypePractitioner - Hospitalist
Provider IdentifiersNPI Number: 1316104060
PECOS PAC ID: 3274670229
Enrollment ID: I20091022000717

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameAlyssa J Stickney
Provider TypePractitioner - Family Practice
Provider IdentifiersNPI Number: 1558490102
PECOS PAC ID: 6103963731
Enrollment ID: I20091029000769

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameCarol J Mccahon
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1871688689
PECOS PAC ID: 7517971146
Enrollment ID: I20091117000214

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameHillary B Starr
Provider TypePractitioner - Family Practice
Provider IdentifiersNPI Number: 1629280326
PECOS PAC ID: 8325187727
Enrollment ID: I20091124000490

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJames A Edwards
Provider TypePractitioner - Plastic And Reconstructive Surgery
Provider IdentifiersNPI Number: 1679680441
PECOS PAC ID: 8729129440
Enrollment ID: I20100104000232

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameRoland V Feltner
Provider TypePractitioner - Family Practice
Provider IdentifiersNPI Number: 1225004658
PECOS PAC ID: 4587705694
Enrollment ID: I20100112000456

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameThejana K Marasinghe
Provider TypePractitioner - Family Practice
Provider IdentifiersNPI Number: 1184777534
PECOS PAC ID: 0941341986
Enrollment ID: I20100112000863

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameRaymond K Whalen
Provider TypePractitioner - Urology
Provider IdentifiersNPI Number: 1851463921
PECOS PAC ID: 3678616869
Enrollment ID: I20100210000631

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameAutumn J Moser
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1962507723
PECOS PAC ID: 8921141110
Enrollment ID: I20100210000660

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameThomas C Skalley
Provider TypePractitioner - Orthopedic Surgery
Provider IdentifiersNPI Number: 1336245976
PECOS PAC ID: 7911041017
Enrollment ID: I20100212000247

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJefferey S Winningham
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1043316110
PECOS PAC ID: 4789728361
Enrollment ID: I20100219000716

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameThomas K Stonecipher
Provider TypePractitioner - Orthopedic Surgery
Provider IdentifiersNPI Number: 1235235490
PECOS PAC ID: 9032253323
Enrollment ID: I20100224000898

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameCristina R Santiago
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1427154053
PECOS PAC ID: 4789729906
Enrollment ID: I20100226000481

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameRussell B Beckley
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1255425799
PECOS PAC ID: 0749320364
Enrollment ID: I20100226000521

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameSigna J Moe
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1740385509
PECOS PAC ID: 8921143157
Enrollment ID: I20100226000533

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameDaniel A Zak
Provider TypePractitioner - Emergency Medicine
Provider IdentifiersNPI Number: 1013965490
PECOS PAC ID: 4981749835
Enrollment ID: I20100303000982

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameChirag A Shah
Provider TypePractitioner - Gynecological Oncology
Provider IdentifiersNPI Number: 1235248360
PECOS PAC ID: 5092850453
Enrollment ID: I20100310000167

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameAmy M Johnson
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1447344031
PECOS PAC ID: 5092840231
Enrollment ID: I20100312000988

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJohn F Mcguigan
Provider TypePractitioner - Clinical Psychologist
Provider IdentifiersNPI Number: 1053461129
PECOS PAC ID: 2264567940
Enrollment ID: I20100319000468

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameBruce A Webster
Provider TypePractitioner - Emergency Medicine
Provider IdentifiersNPI Number: 1770549008
PECOS PAC ID: 5193850600
Enrollment ID: I20100322000796

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameStella C Tanedo
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1790790582
PECOS PAC ID: 0648162545
Enrollment ID: I20100325000711

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameDavid A Lin
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1326143447
PECOS PAC ID: 4880722495
Enrollment ID: I20100430000772

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameRajesh Subramanian
Provider TypePractitioner - Interventional Cardiology
Provider IdentifiersNPI Number: 1265419741
PECOS PAC ID: 1658362272
Enrollment ID: I20100503000492

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameTom M Tocher
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1568571289
PECOS PAC ID: 5991831661
Enrollment ID: I20100504000866

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameEvan Cantini
Provider TypePractitioner - Physical Medicine And Rehabilitation
Provider IdentifiersNPI Number: 1023049244
PECOS PAC ID: 4284521428
Enrollment ID: I20100511000751

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NamePolly R Haberlin
Provider TypePractitioner - Hospitalist
Provider IdentifiersNPI Number: 1467543322
PECOS PAC ID: 5991835407
Enrollment ID: I20100610000086

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NamePatrick E Ryan
Provider TypePractitioner - Cardiac Surgery
Provider IdentifiersNPI Number: 1659328078
PECOS PAC ID: 1658477195
Enrollment ID: I20100630000827

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameTerri A Parsons
Provider TypePractitioner - Physical Medicine And Rehabilitation
Provider IdentifiersNPI Number: 1750495339
PECOS PAC ID: 2365334935
Enrollment ID: I20100712000320

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameRobert Y Choi
Provider TypePractitioner - Infectious Disease
Provider IdentifiersNPI Number: 1962518472
PECOS PAC ID: 9739104746
Enrollment ID: I20100721000650

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameDavid Reed
Provider TypePractitioner - Urology
Provider IdentifiersNPI Number: 1912945791
PECOS PAC ID: 0547394082
Enrollment ID: I20100818001294

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJames M Schmitt
Provider TypePractitioner - Cardiovascular Disease (cardiology)
Provider IdentifiersNPI Number: 1023058229
PECOS PAC ID: 0840315255
Enrollment ID: I20100908000964

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameBudge H Smith
Provider TypePractitioner - Interventional Cardiology
Provider IdentifiersNPI Number: 1427099746
PECOS PAC ID: 9234223801
Enrollment ID: I20100908001014

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJames K Brevig
Provider TypePractitioner - Cardiac Surgery
Provider IdentifiersNPI Number: 1144276106
PECOS PAC ID: 0749386282
Enrollment ID: I20100916000682

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameMichael K Koerner
Provider TypePractitioner - Neurology
Provider IdentifiersNPI Number: 1558337493
PECOS PAC ID: 4688790678
Enrollment ID: I20100928000315

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameMarciano B Capati
Provider TypePractitioner - Family Practice
Provider IdentifiersNPI Number: 1508059486
PECOS PAC ID: 1658564638
Enrollment ID: I20101022000327

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJulie L Jungels
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1639360662
PECOS PAC ID: 6406049352
Enrollment ID: I20101022001324

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameBrad E Talley
Provider TypePractitioner - Emergency Medicine
Provider IdentifiersNPI Number: 1871705780
PECOS PAC ID: 2961552435
Enrollment ID: I20101025001276

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameDaniel J Millikan
Provider TypePractitioner - Emergency Medicine
Provider IdentifiersNPI Number: 1851418040
PECOS PAC ID: 0244423903
Enrollment ID: I20101026000975

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameSarabjit Kaur Atwal
Provider TypePractitioner - Neurology
Provider IdentifiersNPI Number: 1881928414
PECOS PAC ID: 4880888072
Enrollment ID: I20101102000188

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameKristin M Obillo
Provider TypePractitioner - Family Practice
Provider IdentifiersNPI Number: 1235399809
PECOS PAC ID: 7214121185
Enrollment ID: I20101104000703

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameKapil Gangwal
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1891967683
PECOS PAC ID: 0749474625
Enrollment ID: I20101104000834

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameSara K Schepp
Provider TypePractitioner - Neurology
Provider IdentifiersNPI Number: 1568562387
PECOS PAC ID: 4486849221
Enrollment ID: I20101105001294

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameKent K Hu
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1255436432
PECOS PAC ID: 8921293630
Enrollment ID: I20101108000895

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameSean M Burson
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1922312453
PECOS PAC ID: 1951598267
Enrollment ID: I20101213001072

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJoshua Jones
Provider TypePractitioner - Psychiatry
Provider IdentifiersNPI Number: 1548361009
PECOS PAC ID: 5395844591
Enrollment ID: I20110107000627

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameMohamad Imad Haque
Provider TypePractitioner - General Surgery
Provider IdentifiersNPI Number: 1326074345
PECOS PAC ID: 3971697111
Enrollment ID: I20110118000989

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameMolina M Chan
Provider TypePractitioner - Family Practice
Provider IdentifiersNPI Number: 1275727778
PECOS PAC ID: 1355530619
Enrollment ID: I20110118001094

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameKarine J Davis
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1518269059
PECOS PAC ID: 9335329689
Enrollment ID: I20110203001070

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJoy M Chilcote
Provider TypePractitioner - Certified Nurse Midwife (cnm)
Provider IdentifiersNPI Number: 1174830806
PECOS PAC ID: 4587844840
Enrollment ID: I20110203001104

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJames William Rice
Provider TypePractitioner - Family Practice
Provider IdentifiersNPI Number: 1811298441
PECOS PAC ID: 5294916748
Enrollment ID: I20110216001162

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameAmanda B Steen
Provider TypePractitioner - Physical Medicine And Rehabilitation
Provider IdentifiersNPI Number: 1043463565
PECOS PAC ID: 1456537273
Enrollment ID: I20110512000200

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJennifer G Engstrom
Provider TypePractitioner - Family Practice
Provider IdentifiersNPI Number: 1063675346
PECOS PAC ID: 0446437495
Enrollment ID: I20110531000753

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameRuth Thiex
Provider TypePractitioner - Neurosurgery
Provider IdentifiersNPI Number: 1912230988
PECOS PAC ID: 1052599487
Enrollment ID: I20110706000518

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameThomas A Deuel
Provider TypePractitioner - Neurology
Provider IdentifiersNPI Number: 1841496908
PECOS PAC ID: 7416125117
Enrollment ID: I20110725000404

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NamePaul R Seckinger
Provider TypePractitioner - Emergency Medicine
Provider IdentifiersNPI Number: 1235330861
PECOS PAC ID: 8820126709
Enrollment ID: I20110727000618

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJay A Augsburger
Provider TypePractitioner - Psychiatry
Provider IdentifiersNPI Number: 1740400852
PECOS PAC ID: 0941355317
Enrollment ID: I20110818000430

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameHugh L Keegan
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1871741710
PECOS PAC ID: 9537339932
Enrollment ID: I20110822000420

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameCatalina M Draghici
Provider TypePractitioner - Psychiatry
Provider IdentifiersNPI Number: 1255524930
PECOS PAC ID: 2961672704
Enrollment ID: I20110902000345

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameRyan D David
Provider TypePractitioner - Emergency Medicine
Provider IdentifiersNPI Number: 1639301617
PECOS PAC ID: 0143490946
Enrollment ID: I20110906000350

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameRachel A Bates
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1154619054
PECOS PAC ID: 6002087574
Enrollment ID: I20110914000585

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameSujata T Agnani
Provider TypePractitioner - Cardiovascular Disease (cardiology)
Provider IdentifiersNPI Number: 1841305323
PECOS PAC ID: 5496752487
Enrollment ID: I20110921000355

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameSan Sophie Wong
Provider TypePractitioner - Infectious Disease
Provider IdentifiersNPI Number: 1508054826
PECOS PAC ID: 3779643283
Enrollment ID: I20110927000327

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameLisa Maria Ramirez
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1104106640
PECOS PAC ID: 0648442244
Enrollment ID: I20111003000748

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameVictoria L Buchanan
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1699056036
PECOS PAC ID: 7618140914
Enrollment ID: I20111102000319

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameEdward Lee
Provider TypePractitioner - Osteopathic Manipulative Medicine
Provider IdentifiersNPI Number: 1033134267
PECOS PAC ID: 9931008141
Enrollment ID: I20111103000930

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NamePeter B Brant Zawadzki
Provider TypePractitioner - Vascular Surgery
Provider IdentifiersNPI Number: 1215134697
PECOS PAC ID: 0941474167
Enrollment ID: I20111123000635

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameMelissa E Stanley
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1326328758
PECOS PAC ID: 3476729492
Enrollment ID: I20111221000787

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameAixa D Espinosa-morales
Provider TypePractitioner - Neurology
Provider IdentifiersNPI Number: 1851449938
PECOS PAC ID: 5092987651
Enrollment ID: I20120202000201

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NamePatricia Garrison
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1730489972
PECOS PAC ID: 3375722374
Enrollment ID: I20120221000861

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJames W Jordan
Provider TypePractitioner - Neurology
Provider IdentifiersNPI Number: 1417156993
PECOS PAC ID: 3870675002
Enrollment ID: I20120329000427

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameFeng Wang
Provider TypePractitioner - Cardiovascular Disease (cardiology)
Provider IdentifiersNPI Number: 1922283431
PECOS PAC ID: 5395824692
Enrollment ID: I20120409000378

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameRichard B Johnston
Provider TypePractitioner - Urology
Provider IdentifiersNPI Number: 1477839066
PECOS PAC ID: 0345406518
Enrollment ID: I20120717000333

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameNancy O Thordarson
Provider TypePractitioner - Pediatric Medicine
Provider IdentifiersNPI Number: 1962470674
PECOS PAC ID: 4688830862
Enrollment ID: I20120717000375

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameBarbara J Kraynek
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1639307879
PECOS PAC ID: 4082860077
Enrollment ID: I20120807000503

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJohn B Abano
Provider TypePractitioner - Family Practice
Provider IdentifiersNPI Number: 1891929857
PECOS PAC ID: 5092961656
Enrollment ID: I20120814000411

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameMai Won
Provider TypePractitioner - Neurology
Provider IdentifiersNPI Number: 1871676676
PECOS PAC ID: 2860418175
Enrollment ID: I20120816000584

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameElizabeth Stuebing
Provider TypePractitioner - General Surgery
Provider IdentifiersNPI Number: 1992924724
PECOS PAC ID: 6204085921
Enrollment ID: I20121012000259

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameHisam S Goueli
Provider TypePractitioner - Psychiatry
Provider IdentifiersNPI Number: 1639382906
PECOS PAC ID: 3870644776
Enrollment ID: I20121030000555

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameYaw Sarpong
Provider TypePractitioner - Neurosurgery
Provider IdentifiersNPI Number: 1073779435
PECOS PAC ID: 7214188101
Enrollment ID: I20121128000043

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameBenjamin A Zaniello
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1639338544
PECOS PAC ID: 8921250762
Enrollment ID: I20121130000425

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameRachel Mae Fidino
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1568716249
PECOS PAC ID: 4880847276
Enrollment ID: I20130115000405

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameAndrea Freng
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1336436567
PECOS PAC ID: 8628222437
Enrollment ID: I20130201000495

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameSamuel J Youssef
Provider TypePractitioner - General Surgery
Provider IdentifiersNPI Number: 1639330475
PECOS PAC ID: 0547405128
Enrollment ID: I20130402000450

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJoshua Z Press
Provider TypePractitioner - Gynecological Oncology
Provider IdentifiersNPI Number: 1740475383
PECOS PAC ID: 3779729637
Enrollment ID: I20130419000057

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NamePaula D Ruedebusch
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1033342050
PECOS PAC ID: 9537215348
Enrollment ID: I20130514000404

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameRavi Sivasankara Menon
Provider TypePractitioner - Neurology
Provider IdentifiersNPI Number: 1326160177
PECOS PAC ID: 2062572142
Enrollment ID: I20130605000091

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameKatherine I Moreno
Provider TypePractitioner - General Surgery
Provider IdentifiersNPI Number: 1114038437
PECOS PAC ID: 0446499776
Enrollment ID: I20130618000605

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameKashmira Singh
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1194038182
PECOS PAC ID: 6002055241
Enrollment ID: I20130618000850

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameDean Nair
Provider TypePractitioner - Family Practice
Provider IdentifiersNPI Number: 1639481500
PECOS PAC ID: 9638318884
Enrollment ID: I20130618000855

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameBenjamin Atkinson
Provider TypePractitioner - Neurology
Provider IdentifiersNPI Number: 1023256237
PECOS PAC ID: 4183802945
Enrollment ID: I20130620000086

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameAmit J Grover
Provider TypePractitioner - Family Practice
Provider IdentifiersNPI Number: 1114230059
PECOS PAC ID: 2466697990
Enrollment ID: I20130626000203

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameShanshan M Bond
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1861704629
PECOS PAC ID: 5597906446
Enrollment ID: I20130718000792

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameGeoffrey Lowrey
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1730308396
PECOS PAC ID: 3375585862
Enrollment ID: I20130724000330

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameEsther Y Moy
Provider TypePractitioner - Obstetrics/gynecology
Provider IdentifiersNPI Number: 1174782171
PECOS PAC ID: 7618125303
Enrollment ID: I20130731000606

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameAaron N Stayman
Provider TypePractitioner - Neurology
Provider IdentifiersNPI Number: 1477711018
PECOS PAC ID: 9133360142
Enrollment ID: I20130801000848

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameStephen James Monteith
Provider TypePractitioner - Neurosurgery
Provider IdentifiersNPI Number: 1689868119
PECOS PAC ID: 5294977161
Enrollment ID: I20130806000886

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NamePeter M Meis
Provider TypePractitioner - Psychiatry
Provider IdentifiersNPI Number: 1326273632
PECOS PAC ID: 0749422186
Enrollment ID: I20130814000225

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameEric C Chang
Provider TypePractitioner - Neurosurgery
Provider IdentifiersNPI Number: 1538295928
PECOS PAC ID: 3971761727
Enrollment ID: I20130815000194

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameFrederick Stephens
Provider TypePractitioner - Neurosurgery
Provider IdentifiersNPI Number: 1306005988
PECOS PAC ID: 9133397920
Enrollment ID: I20130820001110

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameAnfissa Sokolova
Provider TypePractitioner - Obstetrics/gynecology
Provider IdentifiersNPI Number: 1508009408
PECOS PAC ID: 1759525744
Enrollment ID: I20130912000519

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameBandana K Sharma
Provider TypePractitioner - Family Practice
Provider IdentifiersNPI Number: 1356661573
PECOS PAC ID: 3870737737
Enrollment ID: I20130913000561

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameClara L Peck
Provider TypePractitioner - Hospitalist
Provider IdentifiersNPI Number: 1659563526
PECOS PAC ID: 6002985264
Enrollment ID: I20130917000070

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJennifer Elizabeth Taylor Gaines
Provider TypePractitioner - Certified Nurse Midwife (cnm)
Provider IdentifiersNPI Number: 1841631991
PECOS PAC ID: 3577707264
Enrollment ID: I20130919000238

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameSima G Mistry
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1760625552
PECOS PAC ID: 9436393816
Enrollment ID: I20130925000602

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameDanielle P Waldron
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1851724223
PECOS PAC ID: 6901030378
Enrollment ID: I20131018000696

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameAlison R Putnam
Provider TypePractitioner - Sports Medicine
Provider IdentifiersNPI Number: 1598924417
PECOS PAC ID: 2062648223
Enrollment ID: I20131115001531

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameXiaojing Do Shen
Provider TypePractitioner - Family Practice
Provider IdentifiersNPI Number: 1376856088
PECOS PAC ID: 8224266267
Enrollment ID: I20140120000706

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameThomas W Garges
Provider TypePractitioner - Family Practice
Provider IdentifiersNPI Number: 1255314290
PECOS PAC ID: 4981613106
Enrollment ID: I20140605001958

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameAlireza K Anissipour
Provider TypePractitioner - Orthopedic Surgery
Provider IdentifiersNPI Number: 1033352968
PECOS PAC ID: 4789808692
Enrollment ID: I20140616002270

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameAaditya Singhal
Provider TypePractitioner - Family Practice
Provider IdentifiersNPI Number: 1932413812
PECOS PAC ID: 6608090451
Enrollment ID: I20140617001698

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameMatthew A Hansen
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1104117399
PECOS PAC ID: 0547494973
Enrollment ID: I20140620002114

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameAlexander Salskov
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1972892230
PECOS PAC ID: 9931323417
Enrollment ID: I20140624002326

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameRobert T Dabkowski
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1588955801
PECOS PAC ID: 8921232174
Enrollment ID: I20140630000467

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJohn Peter Biebelhausen
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1942509187
PECOS PAC ID: 4082849161
Enrollment ID: I20140701001847

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameMona Shawky
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1861711210
PECOS PAC ID: 4284877903
Enrollment ID: I20140710001057

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameElise C Willis
Provider TypePractitioner - Hospitalist
Provider IdentifiersNPI Number: 1487953683
PECOS PAC ID: 6800011602
Enrollment ID: I20140711001158

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJake Harley Choiniere
Provider TypePractitioner - Psychiatry
Provider IdentifiersNPI Number: 1578882452
PECOS PAC ID: 4688890155
Enrollment ID: I20140721000051

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameWei-chun Chang
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1104112432
PECOS PAC ID: 9830315761
Enrollment ID: I20140729001803

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameAngela K Muriithi
Provider TypePractitioner - Nephrology
Provider IdentifiersNPI Number: 1770811838
PECOS PAC ID: 6901086917
Enrollment ID: I20140805002365

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJoshua H Urvater
Provider TypePractitioner - Orthopedic Surgery
Provider IdentifiersNPI Number: 1558316703
PECOS PAC ID: 4587668785
Enrollment ID: I20140902001423

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameDonald Henline
Provider TypePractitioner - Orthopedic Surgery
Provider IdentifiersNPI Number: 1356326870
PECOS PAC ID: 8022179241
Enrollment ID: I20140908002705

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameLindsay K Petty
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1255749776
PECOS PAC ID: 3274752977
Enrollment ID: I20140911000461

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NamePhilip H Hassrick
Provider TypePractitioner - Family Practice
Provider IdentifiersNPI Number: 1043207509
PECOS PAC ID: 1456330554
Enrollment ID: I20140918001516

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameDean T Ngo
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1346687274
PECOS PAC ID: 7416177472
Enrollment ID: I20140925002187

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJennifer Wild
Provider TypePractitioner - Pediatric Medicine
Provider IdentifiersNPI Number: 1588953582
PECOS PAC ID: 4688894579
Enrollment ID: I20140926001362

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameYing Liu
Provider TypePractitioner - Obstetrics/gynecology
Provider IdentifiersNPI Number: 1245541903
PECOS PAC ID: 5991925828
Enrollment ID: I20140927000502

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameVikas Sharotri
Provider TypePractitioner - Cardiovascular Disease (cardiology)
Provider IdentifiersNPI Number: 1487870127
PECOS PAC ID: 0941307284
Enrollment ID: I20141008002107

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameAkshal S Patel
Provider TypePractitioner - Neurosurgery
Provider IdentifiersNPI Number: 1447451562
PECOS PAC ID: 1557502721
Enrollment ID: I20141016000725

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameLauren E Johnson
Provider TypePractitioner - Physical Therapist In Private Practice
Provider IdentifiersNPI Number: 1538577010
PECOS PAC ID: 4688895121
Enrollment ID: I20141024002021

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJason A Talavera
Provider TypePractitioner - Cardiovascular Disease (cardiology)
Provider IdentifiersNPI Number: 1568747012
PECOS PAC ID: 5395912943
Enrollment ID: I20141029001682

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameElizabeth G Herskovitz
Provider TypePractitioner - Certified Nurse Midwife (cnm)
Provider IdentifiersNPI Number: 1861771123
PECOS PAC ID: 2163644253
Enrollment ID: I20141104002715

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameVivek Bhatia
Provider TypePractitioner - Cardiovascular Disease (cardiology)
Provider IdentifiersNPI Number: 1699094359
PECOS PAC ID: 3072735943
Enrollment ID: I20141107001594

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJillian Hamel
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1770727307
PECOS PAC ID: 2860544640
Enrollment ID: I20141125001058

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameStephanie D Benson
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1548676752
PECOS PAC ID: 0648592303
Enrollment ID: I20141208001203

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameAnne Camber
Provider TypePractitioner - Obstetrics/gynecology
Provider IdentifiersNPI Number: 1689630840
PECOS PAC ID: 1052315256
Enrollment ID: I20141209002224

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameLesley N Bobek
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1922202787
PECOS PAC ID: 0244377802
Enrollment ID: I20141216000708

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameAdriana N Rosales
Provider TypePractitioner - Family Practice
Provider IdentifiersNPI Number: 1477745248
PECOS PAC ID: 4587802822
Enrollment ID: I20141217001754

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameKitti Kaiboriboon
Provider TypePractitioner - Neurology
Provider IdentifiersNPI Number: 1912062035
PECOS PAC ID: 4284731027
Enrollment ID: I20150130000742

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJacob A Varghese
Provider TypePractitioner - Pediatric Medicine
Provider IdentifiersNPI Number: 1922196013
PECOS PAC ID: 7012935703
Enrollment ID: I20150219000373

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameLisa D Mccabe
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1770972481
PECOS PAC ID: 8820313554
Enrollment ID: I20150220001107

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameOlivia Eisner
Provider TypePractitioner - Certified Nurse Midwife (cnm)
Provider IdentifiersNPI Number: 1013315118
PECOS PAC ID: 5597081208
Enrollment ID: I20150223001853

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameEdward P Bahk
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1184812273
PECOS PAC ID: 2264652429
Enrollment ID: I20150304001569

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameTanner Joe Arey
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1821496431
PECOS PAC ID: 3072839133
Enrollment ID: I20150307000250

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameLinda M Sterritt
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1528458247
PECOS PAC ID: 8628396504
Enrollment ID: I20150407000220

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameNicole F Zickler
Provider TypePractitioner - Certified Nurse Midwife (cnm)
Provider IdentifiersNPI Number: 1962809855
PECOS PAC ID: 2365760782
Enrollment ID: I20150415002277

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameLeonid V Kim
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1407116874
PECOS PAC ID: 1658691696
Enrollment ID: I20150514002582

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameMarion S Johnson
Provider TypePractitioner - Allergy/immunology
Provider IdentifiersNPI Number: 1952523086
PECOS PAC ID: 3375509003
Enrollment ID: I20150601000115

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameDanielle Rosser
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1558773598
PECOS PAC ID: 7517184708
Enrollment ID: I20150602002873

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameSamantha J Quade
Provider TypePractitioner - General Surgery
Provider IdentifiersNPI Number: 1891943221
PECOS PAC ID: 6709107162
Enrollment ID: I20150610001905

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameRichard Cochran
Provider TypePractitioner - Cardiac Surgery
Provider IdentifiersNPI Number: 1013996586
PECOS PAC ID: 8921042870
Enrollment ID: I20150618002541

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameChristina J Sok
Provider TypePractitioner - Obstetrics/gynecology
Provider IdentifiersNPI Number: 1821314980
PECOS PAC ID: 8022249937
Enrollment ID: I20150706001050

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameMartin Holland
Provider TypePractitioner - Neurosurgery
Provider IdentifiersNPI Number: 1780657601
PECOS PAC ID: 9032241856
Enrollment ID: I20150706002387

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NamePeter Hunt
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1962727438
PECOS PAC ID: 0840420873
Enrollment ID: I20150707000118

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameSamuel C Lien
Provider TypePractitioner - Plastic And Reconstructive Surgery
Provider IdentifiersNPI Number: 1285876185
PECOS PAC ID: 0648582114
Enrollment ID: I20150713000664

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameSabrina R Middleton
Provider TypePractitioner - Pediatric Medicine
Provider IdentifiersNPI Number: 1467728964
PECOS PAC ID: 9931412541
Enrollment ID: I20150724010830

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameShawn R Schweitzer
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1225397789
PECOS PAC ID: 1759527864
Enrollment ID: I20150730012197

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameAnnabelle K Dampier
Provider TypePractitioner - Psychiatry
Provider IdentifiersNPI Number: 1164785614
PECOS PAC ID: 5193038966
Enrollment ID: I20150731014846

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NamePuneet Gill
Provider TypePractitioner - Hospitalist
Provider IdentifiersNPI Number: 1902161631
PECOS PAC ID: 0042453565
Enrollment ID: I20150731016518

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameAgnes Borjal
Provider TypePractitioner - Physical Therapist In Private Practice
Provider IdentifiersNPI Number: 1760411557
PECOS PAC ID: 6507861614
Enrollment ID: I20150811004695

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameElizabeth M Gilbert
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1912160953
PECOS PAC ID: 6103993076
Enrollment ID: I20150812007015

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJustin Gill
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1174903603
PECOS PAC ID: 8921314121
Enrollment ID: I20150902002925

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameDavid Keisho Su
Provider TypePractitioner - Neurosurgery
Provider IdentifiersNPI Number: 1083863005
PECOS PAC ID: 4082924048
Enrollment ID: I20151104001416

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameNicole T Mills
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1578934568
PECOS PAC ID: 3870893027
Enrollment ID: I20151119002993

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameMiriam Carla Sorensen
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1376914879
PECOS PAC ID: 3678874898
Enrollment ID: I20151214000272

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameSamantha J Newbould
Provider TypePractitioner - Family Practice
Provider IdentifiersNPI Number: 1790763282
PECOS PAC ID: 1153315858
Enrollment ID: I20151221000537

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameSarah M Meyer
Provider TypePractitioner - Certified Nurse Midwife (cnm)
Provider IdentifiersNPI Number: 1588749451
PECOS PAC ID: 6507010139
Enrollment ID: I20160121000331

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameCandace L Mabbitt
Provider TypePractitioner - Certified Nurse Midwife (cnm)
Provider IdentifiersNPI Number: 1265841159
PECOS PAC ID: 2264737592
Enrollment ID: I20160225000385

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameKathryn E Gilligan
Provider TypePractitioner - Psychiatry
Provider IdentifiersNPI Number: 1962609354
PECOS PAC ID: 0446376677
Enrollment ID: I20160229000458

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameRyan K Hoke
Provider TypePractitioner - Physical Medicine And Rehabilitation
Provider IdentifiersNPI Number: 1700011350
PECOS PAC ID: 3072748920
Enrollment ID: I20160324001003

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameFederico Fenton Portillo
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1891136842
PECOS PAC ID: 5395989222
Enrollment ID: I20160330001964

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameDaniel G Mcclung
Provider TypePractitioner - Infectious Disease
Provider IdentifiersNPI Number: 1629396338
PECOS PAC ID: 4688987787
Enrollment ID: I20160331000808

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameRhonda M Bass
Provider TypePractitioner - Family Practice
Provider IdentifiersNPI Number: 1023014925
PECOS PAC ID: 9032301015
Enrollment ID: I20160406001324

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameMarianna Baghdasaryan
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1164695102
PECOS PAC ID: 9032417860
Enrollment ID: I20160412001651

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameThoa P Fenton
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1326477324
PECOS PAC ID: 6608005806
Enrollment ID: I20160422002088

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameCameron G Mcdougall
Provider TypePractitioner - Neurosurgery
Provider IdentifiersNPI Number: 1598751018
PECOS PAC ID: 4587707864
Enrollment ID: I20160425002584

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameBridget Scott-fletcher
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1619137718
PECOS PAC ID: 0244394583
Enrollment ID: I20160502001256

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameDana Blackham
Provider TypePractitioner - Obstetrics/gynecology
Provider IdentifiersNPI Number: 1356487029
PECOS PAC ID: 7012216427
Enrollment ID: I20160505001212

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameDavid A Hoschek
Provider TypePractitioner - Family Practice
Provider IdentifiersNPI Number: 1942644414
PECOS PAC ID: 5890011696
Enrollment ID: I20160517000851

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameNathaniel Lee Atkin
Provider TypePractitioner - Hospitalist
Provider IdentifiersNPI Number: 1134358344
PECOS PAC ID: 4688828981
Enrollment ID: I20160520001449

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameMike D Berry
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1912368234
PECOS PAC ID: 8820387293
Enrollment ID: I20160525001827

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameAnooradha Raman
Provider TypePractitioner - General Surgery
Provider IdentifiersNPI Number: 1447319801
PECOS PAC ID: 9133219777
Enrollment ID: I20160603001852

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameBrandon J Orr
Provider TypePractitioner - Family Practice
Provider IdentifiersNPI Number: 1982993028
PECOS PAC ID: 4183840994
Enrollment ID: I20160614000981

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameAmy M Barrows
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1225485550
PECOS PAC ID: 4183915895
Enrollment ID: I20160627001822

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameSean E Legg
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1942657416
PECOS PAC ID: 1153612700
Enrollment ID: I20160629000675

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameCarl Jessob Gannon
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1053668335
PECOS PAC ID: 8729228531
Enrollment ID: I20160714000477

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameSean Colin Weaver
Provider TypePractitioner - Emergency Medicine
Provider IdentifiersNPI Number: 1467794032
PECOS PAC ID: 9133413958
Enrollment ID: I20160802001693

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJane Sue Ooi
Provider TypePractitioner - Family Practice
Provider IdentifiersNPI Number: 1093945446
PECOS PAC ID: 3476721085
Enrollment ID: I20160802001827

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameSayed Amirhossein Khademi
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1407271547
PECOS PAC ID: 8224322581
Enrollment ID: I20160809001741

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameMichelle Hadi
Provider TypePractitioner - Family Practice
Provider IdentifiersNPI Number: 1528321221
PECOS PAC ID: 0042441628
Enrollment ID: I20160810000830

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameGuilford T Parsons
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1922441260
PECOS PAC ID: 0244474179
Enrollment ID: I20160815000691

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameSongyan Mao
Provider TypePractitioner - Family Practice
Provider IdentifiersNPI Number: 1235160474
PECOS PAC ID: 2961409263
Enrollment ID: I20160815002129

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameTarvinder Singh
Provider TypePractitioner - Neurology
Provider IdentifiersNPI Number: 1225327091
PECOS PAC ID: 0840505251
Enrollment ID: I20160817001266

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameScott D Schwitz
Provider TypePractitioner - Emergency Medicine
Provider IdentifiersNPI Number: 1124394267
PECOS PAC ID: 9931494465
Enrollment ID: I20160823002821

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameAllison G Moyes
Provider TypePractitioner - Emergency Medicine
Provider IdentifiersNPI Number: 1447526470
PECOS PAC ID: 9830414275
Enrollment ID: I20160826000944

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameBryce S Snow
Provider TypePractitioner - Emergency Medicine
Provider IdentifiersNPI Number: 1720421803
PECOS PAC ID: 0446568562
Enrollment ID: I20160831002195

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameThomas E Robey
Provider TypePractitioner - Emergency Medicine
Provider IdentifiersNPI Number: 1942434675
PECOS PAC ID: 9032368436
Enrollment ID: I20160901000796

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameRebecca A Link
Provider TypePractitioner - Emergency Medicine
Provider IdentifiersNPI Number: 1912273822
PECOS PAC ID: 8729388137
Enrollment ID: I20160901001654

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameMiriam E Levi
Provider TypePractitioner - Certified Nurse Midwife (cnm)
Provider IdentifiersNPI Number: 1538432323
PECOS PAC ID: 3476797838
Enrollment ID: I20160906002031

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJayne M Barkman
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1932559101
PECOS PAC ID: 6800182585
Enrollment ID: I20160906002043

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameSrivani Kanumuri
Provider TypePractitioner - Preventive Medicine
Provider IdentifiersNPI Number: 1336481183
PECOS PAC ID: 3870889553
Enrollment ID: I20160906002125

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameEvan J Kirschner
Provider TypePractitioner - Emergency Medicine
Provider IdentifiersNPI Number: 1700128816
PECOS PAC ID: 2466748116
Enrollment ID: I20160907001625

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameShaina Schaetzel
Provider TypePractitioner - General Surgery
Provider IdentifiersNPI Number: 1801038161
PECOS PAC ID: 9830485069
Enrollment ID: I20160914000807

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameCindy Crystal Beavon
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1376995811
PECOS PAC ID: 7113213224
Enrollment ID: I20160915000759

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameAshley Weisman
Provider TypePractitioner - Emergency Medicine
Provider IdentifiersNPI Number: 1801158324
PECOS PAC ID: 0042464570
Enrollment ID: I20160917000050

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameMartha A Leonard
Provider TypePractitioner - Clinical Social Worker
Provider IdentifiersNPI Number: 1043313554
PECOS PAC ID: 9638466535
Enrollment ID: I20160920002783

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameIlina Bucur
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1881140440
PECOS PAC ID: 7517254311
Enrollment ID: I20160922000241

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameRonald Joseph Quam
Provider TypePractitioner - Orthopedic Surgery
Provider IdentifiersNPI Number: 1306908033
PECOS PAC ID: 0941367478
Enrollment ID: I20160922001296

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJulie E Quandt
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1144673153
PECOS PAC ID: 7012204761
Enrollment ID: I20160922002252

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameKristina L Campbell
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1386199586
PECOS PAC ID: 6507153285
Enrollment ID: I20160923000227

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameDoniel G Drazin
Provider TypePractitioner - Neurosurgery
Provider IdentifiersNPI Number: 1790195790
PECOS PAC ID: 2062709678
Enrollment ID: I20160926002050

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameDana Shuey
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1225407562
PECOS PAC ID: 5799085395
Enrollment ID: I20160926002219

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameRosane J Fernandez
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1821351339
PECOS PAC ID: 6002048170
Enrollment ID: I20160927002496

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameZachary Louis Steinberg
Provider TypePractitioner - Adult Congenital Heart Disease (achd)
Provider IdentifiersNPI Number: 1609023936
PECOS PAC ID: 0345530929
Enrollment ID: I20160928000720

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameRolando I Celis
Provider TypePractitioner - Vascular Surgery
Provider IdentifiersNPI Number: 1497975361
PECOS PAC ID: 5294985529
Enrollment ID: I20160930001973

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameKory Herrick
Provider TypePractitioner - Neurology
Provider IdentifiersNPI Number: 1346484912
PECOS PAC ID: 9638324395
Enrollment ID: I20161010002016

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameRajni Aulakh
Provider TypePractitioner - Psychiatry
Provider IdentifiersNPI Number: 1396034567
PECOS PAC ID: 8123255940
Enrollment ID: I20161012002305

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJulie Ann Hornsby
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1407304587
PECOS PAC ID: 1254610652
Enrollment ID: I20161107001981

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameGale Springer
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1578012183
PECOS PAC ID: 0547549230
Enrollment ID: I20161121002138

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameKim Quy V Nguyen
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1053861161
PECOS PAC ID: 2466733811
Enrollment ID: I20161227001270

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameThomas E Paulson
Provider TypePractitioner - Family Practice
Provider IdentifiersNPI Number: 1497029763
PECOS PAC ID: 2466734181
Enrollment ID: I20170112002163

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameAndrew D Rontal
Provider TypePractitioner - Neurology
Provider IdentifiersNPI Number: 1063657328
PECOS PAC ID: 7911150065
Enrollment ID: I20170223002188

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameLisa R Yanase
Provider TypePractitioner - Neurology
Provider IdentifiersNPI Number: 1851384937
PECOS PAC ID: 1052343167
Enrollment ID: I20170223002540

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameVicky L Hay
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1629203005
PECOS PAC ID: 6608914395
Enrollment ID: I20170227001427

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameGretchen Bower
Provider TypePractitioner - Clinical Social Worker
Provider IdentifiersNPI Number: 1912330556
PECOS PAC ID: 5991089922
Enrollment ID: I20170310001462

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NamePeter J Sumner
Provider TypePractitioner - Neurology
Provider IdentifiersNPI Number: 1073839700
PECOS PAC ID: 7911124045
Enrollment ID: I20170331001986

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameFranchette T Pascual
Provider TypePractitioner - Neurology
Provider IdentifiersNPI Number: 1245491711
PECOS PAC ID: 6305094889
Enrollment ID: I20170504000698

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameYi Mao
Provider TypePractitioner - Neurology
Provider IdentifiersNPI Number: 1629327986
PECOS PAC ID: 0547538118
Enrollment ID: I20170622002818

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJoseph David Nickolas Freeburg
Provider TypePractitioner - Neurology
Provider IdentifiersNPI Number: 1174898381
PECOS PAC ID: 7012224298
Enrollment ID: I20170706002670

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameLauren E Powell
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1750791695
PECOS PAC ID: 9931328440
Enrollment ID: I20170712002193

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameAmy Vannortwick
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1902223365
PECOS PAC ID: 6608193412
Enrollment ID: I20170728002753

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameNatasha Sparrow
Provider TypePractitioner - Neurology
Provider IdentifiersNPI Number: 1326308339
PECOS PAC ID: 9931411600
Enrollment ID: I20170802001726

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameAws Amir Alawi
Provider TypePractitioner - Neurology
Provider IdentifiersNPI Number: 1891082293
PECOS PAC ID: 3870871007
Enrollment ID: I20170807002140

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameAhmed A Salahudeen
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1215372552
PECOS PAC ID: 5799073961
Enrollment ID: I20170811001224

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameCorey White
Provider TypePractitioner - Neurology
Provider IdentifiersNPI Number: 1154610814
PECOS PAC ID: 2961723663
Enrollment ID: I20170811001881

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameVeena Arani
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1508152927
PECOS PAC ID: 8022309749
Enrollment ID: I20170814002374

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameAllie M Massaro
Provider TypePractitioner - Neurology
Provider IdentifiersNPI Number: 1649563503
PECOS PAC ID: 5294007076
Enrollment ID: I20170815002219

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameEalaf Shemmeri
Provider TypePractitioner - General Surgery
Provider IdentifiersNPI Number: 1760749667
PECOS PAC ID: 5395017362
Enrollment ID: I20170825001580

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameCrystal L Blankinship
Provider TypePractitioner - Clinical Social Worker
Provider IdentifiersNPI Number: 1144452319
PECOS PAC ID: 9739453663
Enrollment ID: I20170915002368

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameArun Arora
Provider TypePractitioner - Psychiatry
Provider IdentifiersNPI Number: 1033555925
PECOS PAC ID: 1850519315
Enrollment ID: I20170921002235

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameAshleigh V Leonard
Provider TypePractitioner - Hospitalist
Provider IdentifiersNPI Number: 1689084493
PECOS PAC ID: 5890917132
Enrollment ID: I20170926003831

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameEric D Prince
Provider TypePractitioner - Neurology
Provider IdentifiersNPI Number: 1770843658
PECOS PAC ID: 2567752777
Enrollment ID: I20171002003734

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameSheetal Dhoke
Provider TypePractitioner - Psychiatry
Provider IdentifiersNPI Number: 1144457243
PECOS PAC ID: 2365673589
Enrollment ID: I20171009001246

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameHeather Marie Mcgregor
Provider TypePractitioner - Certified Nurse Midwife (cnm)
Provider IdentifiersNPI Number: 1073872313
PECOS PAC ID: 1153697156
Enrollment ID: I20171018003094

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameKathryn Jors Horton
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1710305578
PECOS PAC ID: 0547584542
Enrollment ID: I20171031000329

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameSana Abbas Jaffri
Provider TypePractitioner - Hospitalist
Provider IdentifiersNPI Number: 1750791125
PECOS PAC ID: 3274752373
Enrollment ID: I20171031001293

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameElisabeth Noel Fisher
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1730607664
PECOS PAC ID: 4587920871
Enrollment ID: I20171101002739

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameSarah A Hutchens
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1710409222
PECOS PAC ID: 5597022061
Enrollment ID: I20171208001281

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameFernanda Md Musa
Provider TypePractitioner - Obstetrics/gynecology
Provider IdentifiersNPI Number: 1700044054
PECOS PAC ID: 2769625243
Enrollment ID: I20171212001736

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameForrest Duen-huei Hsu
Provider TypePractitioner - Neurosurgery
Provider IdentifiersNPI Number: 1346546322
PECOS PAC ID: 8729265350
Enrollment ID: I20171219003141

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameZahra Sadat-hossieny
Provider TypePractitioner - Neurology
Provider IdentifiersNPI Number: 1063754307
PECOS PAC ID: 4183865959
Enrollment ID: I20171222000499

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJoseph Robert Perry
Provider TypePractitioner - Psychiatry
Provider IdentifiersNPI Number: 1134354244
PECOS PAC ID: 8426285917
Enrollment ID: I20180110002318

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameKatie Swerland
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1326564337
PECOS PAC ID: 0547536062
Enrollment ID: I20180213000992

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameCarlos Elias Garcia
Provider TypePractitioner - Thoracic Surgery
Provider IdentifiersNPI Number: 1942216890
PECOS PAC ID: 2163417262
Enrollment ID: I20180219001557

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJoshua A Ort
Provider TypePractitioner - Emergency Medicine
Provider IdentifiersNPI Number: 1508097320
PECOS PAC ID: 1153587886
Enrollment ID: I20180228000697

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameKelly Lynn Dempsey
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1366952798
PECOS PAC ID: 6204197361
Enrollment ID: I20180306001372

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameStephenejo Shaunielle Swift
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1922522093
PECOS PAC ID: 2769744432
Enrollment ID: I20180315002166

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameBrad A. Ward
Provider TypePractitioner - Neurosurgery
Provider IdentifiersNPI Number: 1255337663
PECOS PAC ID: 7810071180
Enrollment ID: I20180321001738

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameAarica Arora
Provider TypePractitioner - Family Practice
Provider IdentifiersNPI Number: 1902322274
PECOS PAC ID: 3779846720
Enrollment ID: I20180404002290

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameAmilyn Taplin
Provider TypePractitioner - Neurosurgery
Provider IdentifiersNPI Number: 1295027472
PECOS PAC ID: 0648539130
Enrollment ID: I20180507000546

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameAbdelrahman Fouad Ahmed Beltagy
Provider TypePractitioner - Neurology
Provider IdentifiersNPI Number: 1013250216
PECOS PAC ID: 0840592572
Enrollment ID: I20180615002091

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameCaroline Ruth Seiler
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1144734328
PECOS PAC ID: 7618223876
Enrollment ID: I20180702002319

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameMatthew J Kalisz
Provider TypePractitioner - Emergency Medicine
Provider IdentifiersNPI Number: 1477993285
PECOS PAC ID: 4688987654
Enrollment ID: I20180720002204

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameRebecca Taulbee
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1144521063
PECOS PAC ID: 0345420675
Enrollment ID: I20180725002632

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameDavid Lee Murphy
Provider TypePractitioner - Emergency Medicine
Provider IdentifiersNPI Number: 1134515729
PECOS PAC ID: 5799096673
Enrollment ID: I20180725003238

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameHwinei Joanna Tavengwa
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1639564933
PECOS PAC ID: 5092035360
Enrollment ID: I20180807002457

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJoshua P Schilling
Provider TypePractitioner - Cardiovascular Disease (cardiology)
Provider IdentifiersNPI Number: 1417219874
PECOS PAC ID: 7618297169
Enrollment ID: I20180807003423

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameGrace Erin Oppenheim
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1013355411
PECOS PAC ID: 0749423929
Enrollment ID: I20180813002656

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameDean Tanner
Provider TypePractitioner - Emergency Medicine
Provider IdentifiersNPI Number: 1093102253
PECOS PAC ID: 0042588980
Enrollment ID: I20180816001534

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameTyler Kent
Provider TypePractitioner - Orthopedic Surgery
Provider IdentifiersNPI Number: 1336439116
PECOS PAC ID: 3375892730
Enrollment ID: I20180817000635

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NamePeter Benjamin Toth
Provider TypePractitioner - Emergency Medicine
Provider IdentifiersNPI Number: 1306105275
PECOS PAC ID: 2466691951
Enrollment ID: I20180820001736

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameAmy Wei-ming Liu
Provider TypePractitioner - Hospitalist
Provider IdentifiersNPI Number: 1548654023
PECOS PAC ID: 6507174042
Enrollment ID: I20180823003186

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameThomas Chan
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1043663446
PECOS PAC ID: 9537457999
Enrollment ID: I20180824002123

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameNathaniel Winer
Provider TypePractitioner - Endocrinology
Provider IdentifiersNPI Number: 1245225598
PECOS PAC ID: 1052413671
Enrollment ID: I20180828002610

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJoshua Corsa
Provider TypePractitioner - General Surgery
Provider IdentifiersNPI Number: 1710249123
PECOS PAC ID: 5799921912
Enrollment ID: I20180828003837

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameNicole Kraker
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1285176024
PECOS PAC ID: 2264715648
Enrollment ID: I20180828004219

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameZane Alexander Tymchak
Provider TypePractitioner - Neurosurgery
Provider IdentifiersNPI Number: 1568949055
PECOS PAC ID: 8022368570
Enrollment ID: I20180905001133

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameOlga V Demina
Provider TypePractitioner - Cardiovascular Disease (cardiology)
Provider IdentifiersNPI Number: 1376819367
PECOS PAC ID: 2264747054
Enrollment ID: I20180906003101

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameMichelle Renee Seavey
Provider TypePractitioner - Obstetrics/gynecology
Provider IdentifiersNPI Number: 1114081833
PECOS PAC ID: 7911099197
Enrollment ID: I20180910000820

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameSafina S Hossain
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1508251943
PECOS PAC ID: 5991017154
Enrollment ID: I20180913001925

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJoanna C N Agena
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1750656641
PECOS PAC ID: 4486810439
Enrollment ID: I20180920001000

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameMatthew Salazar Surrusco
Provider TypePractitioner - General Surgery
Provider IdentifiersNPI Number: 1841559820
PECOS PAC ID: 2163798604
Enrollment ID: I20181005001104

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NamePeter B Bartline
Provider TypePractitioner - Vascular Surgery
Provider IdentifiersNPI Number: 1902121635
PECOS PAC ID: 0042442295
Enrollment ID: I20181010003793

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameRoland Abel Hernandez
Provider TypePractitioner - Thoracic Surgery
Provider IdentifiersNPI Number: 1720213580
PECOS PAC ID: 1456603885
Enrollment ID: I20181011002419

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJonathan Paul Salud
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1225423403
PECOS PAC ID: 8325390719
Enrollment ID: I20181012001872

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJason Lee Codding
Provider TypePractitioner - Orthopedic Surgery
Provider IdentifiersNPI Number: 1710245071
PECOS PAC ID: 9638392822
Enrollment ID: I20181024002249

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameLuann Lee Sines
Provider TypePractitioner - Clinical Social Worker
Provider IdentifiersNPI Number: 1497819718
PECOS PAC ID: 4385658772
Enrollment ID: I20181024002727

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJacob Jackson Glaser
Provider TypePractitioner - General Surgery
Provider IdentifiersNPI Number: 1710958046
PECOS PAC ID: 8022235431
Enrollment ID: I20181113001027

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJeremy Rt King
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1073000345
PECOS PAC ID: 4082958038
Enrollment ID: I20181203002876

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJackelin Q Tran
Provider TypePractitioner - Family Practice
Provider IdentifiersNPI Number: 1457748675
PECOS PAC ID: 9537404058
Enrollment ID: I20190102001564

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameBabu Chalam
Provider TypePractitioner - Family Practice
Provider IdentifiersNPI Number: 1598051633
PECOS PAC ID: 3173746500
Enrollment ID: I20190103001387

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameKatie Uberti
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1003382292
PECOS PAC ID: 5092051458
Enrollment ID: I20190107002676

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameDelaney Conway Goulet
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1477990596
PECOS PAC ID: 7416174826
Enrollment ID: I20190208001862

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameAkanksha Sharma
Provider TypePractitioner - Neurology
Provider IdentifiersNPI Number: 1124361712
PECOS PAC ID: 5991023624
Enrollment ID: I20190214002574

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameAndrew Thomas Gomez
Provider TypePractitioner - Family Practice
Provider IdentifiersNPI Number: 1841619418
PECOS PAC ID: 9830491687
Enrollment ID: I20190409000765

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameRichard Lee
Provider TypePractitioner - Thoracic Surgery
Provider IdentifiersNPI Number: 1437476934
PECOS PAC ID: 1254649106
Enrollment ID: I20190509000241

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameMartha Fitelson
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1386023133
PECOS PAC ID: 5597077198
Enrollment ID: I20190605003204

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameAshley L Grieve
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1396302477
PECOS PAC ID: 4284968819
Enrollment ID: I20190701002123

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameKara E Sawyer
Provider TypePractitioner - Emergency Medicine
Provider IdentifiersNPI Number: 1689092561
PECOS PAC ID: 5496036576
Enrollment ID: I20190715002858

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NamePatrick Dillon Bender
Provider TypePractitioner - Emergency Medicine
Provider IdentifiersNPI Number: 1780074500
PECOS PAC ID: 9830405471
Enrollment ID: I20190715003370

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameChad Mayer
Provider TypePractitioner - Emergency Medicine
Provider IdentifiersNPI Number: 1770933467
PECOS PAC ID: 2668768995
Enrollment ID: I20190729001433

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameDaniel Warren Smith
Provider TypePractitioner - Urology
Provider IdentifiersNPI Number: 1043653942
PECOS PAC ID: 7810139557
Enrollment ID: I20190729002082

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameTasneem Abbas Shikary
Provider TypePractitioner - Otolaryngology
Provider IdentifiersNPI Number: 1003105867
PECOS PAC ID: 8426296732
Enrollment ID: I20190729003693

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameCynthia Ramsey
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1003872789
PECOS PAC ID: 5395820864
Enrollment ID: I20190730004292

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameDarya C Khalili
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1275192841
PECOS PAC ID: 4880920651
Enrollment ID: I20190731003786

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameDarren Bowe
Provider TypePractitioner - General Surgery
Provider IdentifiersNPI Number: 1700028750
PECOS PAC ID: 9436460946
Enrollment ID: I20190801002792

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameLisa Mitchell
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1760049449
PECOS PAC ID: 5991032294
Enrollment ID: I20190808003969

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameEugene Shchytou
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1063074169
PECOS PAC ID: 3678800596
Enrollment ID: I20190814003072

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameAngela Phung
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1356903694
PECOS PAC ID: 6406184233
Enrollment ID: I20190819000590

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameOliver C Bellevue
Provider TypePractitioner - General Surgery
Provider IdentifiersNPI Number: 1457771636
PECOS PAC ID: 2062730948
Enrollment ID: I20190820003288

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJavier Herrera
Provider TypePractitioner - General Surgery
Provider IdentifiersNPI Number: 1851359467
PECOS PAC ID: 3274429055
Enrollment ID: I20190827003219

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameChan Wu
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1073926309
PECOS PAC ID: 6709001357
Enrollment ID: I20190830002406

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameChristina A Morse
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1912369828
PECOS PAC ID: 4082907993
Enrollment ID: I20190906002430

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJames F Wang
Provider TypePractitioner - Neurology
Provider IdentifiersNPI Number: 1962829093
PECOS PAC ID: 7012232655
Enrollment ID: I20190910002212

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameMichele Lobitz
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1386639482
PECOS PAC ID: 7517908098
Enrollment ID: I20190923001971

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameVikram M Gopal
Provider TypePractitioner - Psychiatry
Provider IdentifiersNPI Number: 1033401518
PECOS PAC ID: 7618121955
Enrollment ID: I20190924001588

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameMarilyn Sherris
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1700240371
PECOS PAC ID: 0547553703
Enrollment ID: I20190926001839

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameRebecca E Stafford
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1811157191
PECOS PAC ID: 2062687239
Enrollment ID: I20190930003008

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameChristopher Mark Freeman
Provider TypePractitioner - General Surgery
Provider IdentifiersNPI Number: 1386933323
PECOS PAC ID: 5496997496
Enrollment ID: I20191001002933

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameAmare Melak Kassahun
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1538721881
PECOS PAC ID: 1153653001
Enrollment ID: I20191028000543

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameReginah I Nampinga
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1104394097
PECOS PAC ID: 4183956964
Enrollment ID: I20191028002468

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameEmily K Garrett
Provider TypePractitioner - Obstetrics/gynecology
Provider IdentifiersNPI Number: 1811378870
PECOS PAC ID: 0143552893
Enrollment ID: I20191029002820

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameLien B Nguyen
Provider TypePractitioner - Neurology
Provider IdentifiersNPI Number: 1023402914
PECOS PAC ID: 9830404417
Enrollment ID: I20191030002908

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameCarson Van Sanford
Provider TypePractitioner - Neurology
Provider IdentifiersNPI Number: 1669869574
PECOS PAC ID: 9537471149
Enrollment ID: I20191216000256

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameAmil Rafiq
Provider TypePractitioner - Hospitalist
Provider IdentifiersNPI Number: 1669785804
PECOS PAC ID: 4880812452
Enrollment ID: I20191226001504

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameDouglas R Mailman
Provider TypePractitioner - Addiction Medicine
Provider IdentifiersNPI Number: 1528504891
PECOS PAC ID: 6709219314
Enrollment ID: I20191230001993

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameOmar M Saine
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1679121966
PECOS PAC ID: 3678907482
Enrollment ID: I20200103001464

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameMatthew Mcgillvray Hall
Provider TypePractitioner - Emergency Medicine
Provider IdentifiersNPI Number: 1962764522
PECOS PAC ID: 4284947904
Enrollment ID: I20200122002597

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameKristin Louise Wilcox
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1306293337
PECOS PAC ID: 9638458938
Enrollment ID: I20200203002563

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameLorri Jean Hanson
Provider TypePractitioner - Clinical Social Worker
Provider IdentifiersNPI Number: 1861957565
PECOS PAC ID: 9335575307
Enrollment ID: I20200211001596

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJamie Marie Olsen
Provider TypePractitioner - Clinical Social Worker
Provider IdentifiersNPI Number: 1770076440
PECOS PAC ID: 7113353111
Enrollment ID: I20200211002604

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameHallie A Granville
Provider TypePractitioner - Certified Nurse Midwife (cnm)
Provider IdentifiersNPI Number: 1649814658
PECOS PAC ID: 5799112553
Enrollment ID: I20200218000711

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameGeorge Lopez
Provider TypePractitioner - Neurology
Provider IdentifiersNPI Number: 1578588752
PECOS PAC ID: 9638172034
Enrollment ID: I20200224000997

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameWendell Sylvester
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1992255459
PECOS PAC ID: 8426487323
Enrollment ID: I20200330001272

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameSiu Ling Lui
Provider TypePractitioner - Physical Therapist In Private Practice
Provider IdentifiersNPI Number: 1881956035
PECOS PAC ID: 0840629234
Enrollment ID: I20200406003227

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameMollie Marie Sharp
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1558752170
PECOS PAC ID: 8628408614
Enrollment ID: I20200414003381

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameRaymond Aguilar
Provider TypePractitioner - Family Practice
Provider IdentifiersNPI Number: 1871024083
PECOS PAC ID: 5092146431
Enrollment ID: I20200519000670

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameAmy Walker
Provider TypePractitioner - Emergency Medicine
Provider IdentifiersNPI Number: 1407201403
PECOS PAC ID: 6709177439
Enrollment ID: I20200519001898

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameDara Headrick
Provider TypePractitioner - Physical Medicine And Rehabilitation
Provider IdentifiersNPI Number: 1912963711
PECOS PAC ID: 0446242465
Enrollment ID: I20200519002825

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameNathan M Peck
Provider TypePractitioner - Emergency Medicine
Provider IdentifiersNPI Number: 1972034874
PECOS PAC ID: 9133466766
Enrollment ID: I20200610000145

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NamePrabhat Bhama
Provider TypePractitioner - Otolaryngology
Provider IdentifiersNPI Number: 1962415430
PECOS PAC ID: 6901024694
Enrollment ID: I20200618000808

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameShameka L Bolton
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1568700029
PECOS PAC ID: 9032330675
Enrollment ID: I20200624001977

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameYihan Yang
Provider TypePractitioner - Hospitalist
Provider IdentifiersNPI Number: 1568875748
PECOS PAC ID: 4880907328
Enrollment ID: I20200709001131

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameHannah Nicole Lawrence
Provider TypePractitioner - Physical Therapist In Private Practice
Provider IdentifiersNPI Number: 1992323927
PECOS PAC ID: 9234552803
Enrollment ID: I20200715000847

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameRoxanne Ghazvinian
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1225561038
PECOS PAC ID: 2567715824
Enrollment ID: I20200717001185

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJaclyn Marie Lemon
Provider TypePractitioner - Hospitalist
Provider IdentifiersNPI Number: 1144754698
PECOS PAC ID: 4880962943
Enrollment ID: I20200717002375

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameHelen Z Zhang
Provider TypePractitioner - Psychiatry
Provider IdentifiersNPI Number: 1053774000
PECOS PAC ID: 6103117619
Enrollment ID: I20200720000436

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameChad Aaron Rieck
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1285167676
PECOS PAC ID: 7113295379
Enrollment ID: I20200727000532

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameHanbing Wang
Provider TypePractitioner - Neurology
Provider IdentifiersNPI Number: 1679927784
PECOS PAC ID: 3779907522
Enrollment ID: I20200727001289

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameRonald Lawrence Lowell
Provider TypePractitioner - Clinical Social Worker
Provider IdentifiersNPI Number: 1396854139
PECOS PAC ID: 4284058058
Enrollment ID: I20200727001941

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameSierra L Mccreery
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1407380538
PECOS PAC ID: 0547530180
Enrollment ID: I20200728000606

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameLinda Ding
Provider TypePractitioner - General Surgery
Provider IdentifiersNPI Number: 1902123094
PECOS PAC ID: 3072809508
Enrollment ID: I20200803001790

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameBushra Rahman
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1407389448
PECOS PAC ID: 6800212937
Enrollment ID: I20200819001850

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameKyle Yuichi Ogami
Provider TypePractitioner - Neurology
Provider IdentifiersNPI Number: 1801276571
PECOS PAC ID: 9638471626
Enrollment ID: I20200819003829

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameDaniel Kim
Provider TypePractitioner - Vascular Surgery
Provider IdentifiersNPI Number: 1639513229
PECOS PAC ID: 9537309448
Enrollment ID: I20200824000240

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameCarly Elizabeth Hudelson
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1356875413
PECOS PAC ID: 2466879283
Enrollment ID: I20200825002406

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameMichael Meng Chen
Provider TypePractitioner - Neurology
Provider IdentifiersNPI Number: 1558757757
PECOS PAC ID: 9335424449
Enrollment ID: I20200827002834

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameDerek Ting Yu
Provider TypePractitioner - Neurology
Provider IdentifiersNPI Number: 1568889731
PECOS PAC ID: 5991068363
Enrollment ID: I20200903003199

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameWendy Hansen
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1659806164
PECOS PAC ID: 9032482823
Enrollment ID: I20200919000054

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameLaura Marie Marx
Provider TypePractitioner - Physical Therapist In Private Practice
Provider IdentifiersNPI Number: 1528422250
PECOS PAC ID: 7113346784
Enrollment ID: I20200930003405

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameIsha Shrestha
Provider TypePractitioner - Endocrinology
Provider IdentifiersNPI Number: 1477965507
PECOS PAC ID: 0840415758
Enrollment ID: I20201001003518

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameKirstin Anita Hansen
Provider TypePractitioner - Family Practice
Provider IdentifiersNPI Number: 1467973917
PECOS PAC ID: 5092134445
Enrollment ID: I20201002002897

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameRhadika Souza
Provider TypePractitioner - Emergency Medicine
Provider IdentifiersNPI Number: 1013361518
PECOS PAC ID: 7911292784
Enrollment ID: I20201023000814

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NamePriya Deka
Provider TypePractitioner - Obstetrics/gynecology
Provider IdentifiersNPI Number: 1831538867
PECOS PAC ID: 0345514741
Enrollment ID: I20201201002371

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJenniffer Janowiecki
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1871051730
PECOS PAC ID: 1355754425
Enrollment ID: I20210108002233

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameSandeep Kaur Grewal
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1275165227
PECOS PAC ID: 9830502921
Enrollment ID: I20210111000296

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameIrina Shtanko
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1477141059
PECOS PAC ID: 3678987450
Enrollment ID: I20210208001050

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameChristine Cho
Provider TypePractitioner - Infectious Disease
Provider IdentifiersNPI Number: 1518225689
PECOS PAC ID: 0446569800
Enrollment ID: I20210212000262

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJason Soh
Provider TypePractitioner - Pediatric Medicine
Provider IdentifiersNPI Number: 1689092264
PECOS PAC ID: 9032337720
Enrollment ID: I20210226001893

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameTheresa Timmes King
Provider TypePractitioner - Hospitalist
Provider IdentifiersNPI Number: 1083111918
PECOS PAC ID: 3577811090
Enrollment ID: I20210330002077

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJohn Casey
Provider TypePractitioner - Psychiatry
Provider IdentifiersNPI Number: 1841633732
PECOS PAC ID: 1153646955
Enrollment ID: I20210426002444

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJ Drake Oakley
Provider TypePractitioner - Clinical Social Worker
Provider IdentifiersNPI Number: 1588245542
PECOS PAC ID: 7012326879
Enrollment ID: I20210506002391

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameAlexander Malloy
Provider TypePractitioner - General Surgery
Provider IdentifiersNPI Number: 1174886824
PECOS PAC ID: 2668805680
Enrollment ID: I20210510001245

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameLauren Kay Nichole Collins
Provider TypePractitioner - Clinical Social Worker
Provider IdentifiersNPI Number: 1447833322
PECOS PAC ID: 4385043728
Enrollment ID: I20210604000766

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameAnukrati Shukla
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1104311091
PECOS PAC ID: 8628478955
Enrollment ID: I20210608002985

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameMarianne H Yacyshyn
Provider TypePractitioner - Neurology
Provider IdentifiersNPI Number: 1184158875
PECOS PAC ID: 2769751882
Enrollment ID: I20210616003297

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NamePhoebe Jensen
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1912448275
PECOS PAC ID: 5991121246
Enrollment ID: I20210621003025

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameDharscika Arudkumaran
Provider TypePractitioner - Endocrinology
Provider IdentifiersNPI Number: 1396199071
PECOS PAC ID: 1850645144
Enrollment ID: I20210623003266

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameAlexander Katz
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1295276558
PECOS PAC ID: 5294150421
Enrollment ID: I20210715001283

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameWilliam Lou
Provider TypePractitioner - Neurology
Provider IdentifiersNPI Number: 1710340161
PECOS PAC ID: 9830481241
Enrollment ID: I20210723003232

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameAlex Adams Wertheimer
Provider TypePractitioner - Emergency Medicine
Provider IdentifiersNPI Number: 1427440221
PECOS PAC ID: 3274870563
Enrollment ID: I20210726000012

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameBenjamin Richard Huebner
Provider TypePractitioner - General Surgery
Provider IdentifiersNPI Number: 1831533108
PECOS PAC ID: 8325278815
Enrollment ID: I20210727002705

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameShilpa Samudrala
Provider TypePractitioner - Neurology
Provider IdentifiersNPI Number: 1881045433
PECOS PAC ID: 2668898040
Enrollment ID: I20210727003620

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameVictor Wong
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1780173575
PECOS PAC ID: 4385048180
Enrollment ID: I20210802000383

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameDanielle C Hanssen
Provider TypePractitioner - Hospitalist
Provider IdentifiersNPI Number: 1598260721
PECOS PAC ID: 9537415047
Enrollment ID: I20210805001722

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameMark Md Tom
Provider TypePractitioner - Family Practice
Provider IdentifiersNPI Number: 1144712639
PECOS PAC ID: 1153725437
Enrollment ID: I20210809002402

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameAshley N Skluzacek
Provider TypePractitioner - Certified Nurse Midwife (cnm)
Provider IdentifiersNPI Number: 1003240920
PECOS PAC ID: 9830594779
Enrollment ID: I20210816002954

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameHeather D Mai-roecker
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1174836084
PECOS PAC ID: 7517150758
Enrollment ID: I20210824000702

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameEllen French
Provider TypePractitioner - Certified Nurse Midwife (cnm)
Provider IdentifiersNPI Number: 1396204004
PECOS PAC ID: 5496151250
Enrollment ID: I20210902002964

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameNorah An Nguyen
Provider TypePractitioner - Family Practice
Provider IdentifiersNPI Number: 1922503366
PECOS PAC ID: 3274939921
Enrollment ID: I20210907000895

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameRebecca Touger
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1699137265
PECOS PAC ID: 2769773340
Enrollment ID: I20210908003950

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJessica Rakonza
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1730685470
PECOS PAC ID: 3476809203
Enrollment ID: I20210909003960

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameLeila Raminfar
Provider TypePractitioner - Family Practice
Provider IdentifiersNPI Number: 1104323112
PECOS PAC ID: 9234535626
Enrollment ID: I20210910000279

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameSarah Whybark
Provider TypePractitioner - Clinical Social Worker
Provider IdentifiersNPI Number: 1679247324
PECOS PAC ID: 5597161901
Enrollment ID: I20210910000818

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJu Choe
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1780255661
PECOS PAC ID: 3072919240
Enrollment ID: I20210914001260

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameSandeep K Sharma
Provider TypePractitioner - Cardiovascular Disease (cardiology)
Provider IdentifiersNPI Number: 1902091663
PECOS PAC ID: 5395822613
Enrollment ID: I20210927003063

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameChristopher M Brown
Provider TypePractitioner - Neurology
Provider IdentifiersNPI Number: 1891173043
PECOS PAC ID: 1355689381
Enrollment ID: I20210929001168

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameMichael Scott Lallemand
Provider TypePractitioner - General Surgery
Provider IdentifiersNPI Number: 1417393489
PECOS PAC ID: 6709193733
Enrollment ID: I20211012001458

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameNhat B Pham
Provider TypePractitioner - Osteopathic Manipulative Medicine
Provider IdentifiersNPI Number: 1972098606
PECOS PAC ID: 9032465067
Enrollment ID: I20211014000762

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameAnna H Tran
Provider TypePractitioner - Hospitalist
Provider IdentifiersNPI Number: 1558373431
PECOS PAC ID: 8022114909
Enrollment ID: I20211014003426

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameMarie Elizabeth Erickson
Provider TypePractitioner - Clinical Social Worker
Provider IdentifiersNPI Number: 1538368964
PECOS PAC ID: 1052711173
Enrollment ID: I20211018002502

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameSagar Mallikethi Lepakshi Reddy
Provider TypePractitioner - Cardiovascular Disease (cardiology)
Provider IdentifiersNPI Number: 1063790467
PECOS PAC ID: 1456647528
Enrollment ID: I20211019003197

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameRamana Gorrepati
Provider TypePractitioner - Neurosurgery
Provider IdentifiersNPI Number: 1295154375
PECOS PAC ID: 0749509354
Enrollment ID: I20211117002714

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameAnoopa Mathew Jacob
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1982368767
PECOS PAC ID: 7214327063
Enrollment ID: I20211209001546

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJohn R Handy
Provider TypePractitioner - Thoracic Surgery
Provider IdentifiersNPI Number: 1932191467
PECOS PAC ID: 5597663146
Enrollment ID: I20211209001584

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameShreeya Popat
Provider TypePractitioner - Urology
Provider IdentifiersNPI Number: 1215399340
PECOS PAC ID: 0042610982
Enrollment ID: I20211222001343

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameWinokuli Bertrand
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1104215219
PECOS PAC ID: 3870810096
Enrollment ID: I20211229000966

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameKavyashri Kodlipet Jagadeesh
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1013296771
PECOS PAC ID: 5193943983
Enrollment ID: I20220104001312

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NamePadma Srigiriraju
Provider TypePractitioner - Physical Medicine And Rehabilitation
Provider IdentifiersNPI Number: 1043388812
PECOS PAC ID: 2769457696
Enrollment ID: I20220113000956

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameToshiko Oikawa Luckow
Provider TypePractitioner - Family Practice
Provider IdentifiersNPI Number: 1629394572
PECOS PAC ID: 2961644810
Enrollment ID: I20220204001194

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJohn Yonge
Provider TypePractitioner - General Surgery
Provider IdentifiersNPI Number: 1841636941
PECOS PAC ID: 3779977855
Enrollment ID: I20220307001653

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameSmitha Krishnan
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1871974642
PECOS PAC ID: 4284974338
Enrollment ID: I20220318002138

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameAlison Pfeffer
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1275634255
PECOS PAC ID: 3173809977
Enrollment ID: I20220324001237

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameAvigile Baehr
Provider TypePractitioner - Emergency Medicine
Provider IdentifiersNPI Number: 1285096594
PECOS PAC ID: 0042549362
Enrollment ID: I20220324002025

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameParker R Fillmore
Provider TypePractitioner - Critical Care (intensivists)
Provider IdentifiersNPI Number: 1417155086
PECOS PAC ID: 4183845183
Enrollment ID: I20220329000905

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameMark A Parra
Provider TypePractitioner - Obstetrics/gynecology
Provider IdentifiersNPI Number: 1053387431
PECOS PAC ID: 8527002716
Enrollment ID: I20220329002759

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameLucas Mcguire
Provider TypePractitioner - Emergency Medicine
Provider IdentifiersNPI Number: 1528521176
PECOS PAC ID: 8921430646
Enrollment ID: I20220517000606

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameDaniel J Roubik
Provider TypePractitioner - General Surgery
Provider IdentifiersNPI Number: 1922414663
PECOS PAC ID: 5395124770
Enrollment ID: I20220614003378

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameElizabeth Jane Westling
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1699271874
PECOS PAC ID: 9638426315
Enrollment ID: I20220617002676

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameSasha K Kaiser
Provider TypePractitioner - Emergency Medicine
Provider IdentifiersNPI Number: 1003261975
PECOS PAC ID: 0840617999
Enrollment ID: I20220623000301

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameSamuel Frankel
Provider TypePractitioner - Emergency Medicine
Provider IdentifiersNPI Number: 1659934545
PECOS PAC ID: 4183059611
Enrollment ID: I20220627001411

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameSandra Thao Truong
Provider TypePractitioner - Emergency Medicine
Provider IdentifiersNPI Number: 1326535543
PECOS PAC ID: 1052667698
Enrollment ID: I20220708002964

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameZachary J Forcade
Provider TypePractitioner - Emergency Medicine
Provider IdentifiersNPI Number: 1568959559
PECOS PAC ID: 1759638547
Enrollment ID: I20220711001047

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameClaire Jacqueline Chavez
Provider TypePractitioner - General Surgery
Provider IdentifiersNPI Number: 1659638278
PECOS PAC ID: 8628341922
Enrollment ID: I20220720001104

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameGregory J Cannarsa
Provider TypePractitioner - Neurosurgery
Provider IdentifiersNPI Number: 1669866539
PECOS PAC ID: 2769789544
Enrollment ID: I20220721003002

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJosephine Wright
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1164884391
PECOS PAC ID: 1254697907
Enrollment ID: I20220726003114

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameColleen M Koorn
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1023755774
PECOS PAC ID: 1759763410
Enrollment ID: I20220728000917

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameGranger J Marsden
Provider TypePractitioner - Emergency Medicine
Provider IdentifiersNPI Number: 1659866903
PECOS PAC ID: 3072858380
Enrollment ID: I20220802001645

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameMichael Addison Bonelli
Provider TypePractitioner - Hospitalist
Provider IdentifiersNPI Number: 1952965097
PECOS PAC ID: 6901133107
Enrollment ID: I20220809000563

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameRenee Monteiro
Provider TypePractitioner - Family Practice
Provider IdentifiersNPI Number: 1932540242
PECOS PAC ID: 0042516601
Enrollment ID: I20220810000824

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameBrittany Buescher
Provider TypePractitioner - Family Practice
Provider IdentifiersNPI Number: 1053979526
PECOS PAC ID: 3476889668
Enrollment ID: I20220810003623

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameSoo Young Kwon
Provider TypePractitioner - Neurology
Provider IdentifiersNPI Number: 1497199210
PECOS PAC ID: 2365686474
Enrollment ID: I20220816003257

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameAndrew Huang
Provider TypePractitioner - Emergency Medicine
Provider IdentifiersNPI Number: 1144753039
PECOS PAC ID: 3678842945
Enrollment ID: I20220816003455

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameShelby A Reiter
Provider TypePractitioner - General Surgery
Provider IdentifiersNPI Number: 1477084770
PECOS PAC ID: 1658641998
Enrollment ID: I20220823001490

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameGiang C Nguyen
Provider TypePractitioner - Psychiatry
Provider IdentifiersNPI Number: 1558852848
PECOS PAC ID: 8628325073
Enrollment ID: I20220912000419

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJeneeca C Johnston
Provider TypePractitioner - Family Practice
Provider IdentifiersNPI Number: 1720586977
PECOS PAC ID: 8628309739
Enrollment ID: I20220914001588

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameOliver B Orr
Provider TypePractitioner - Hospitalist
Provider IdentifiersNPI Number: 1316506264
PECOS PAC ID: 9335474766
Enrollment ID: I20220920000679

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameEunice M Marpaung
Provider TypePractitioner - Family Practice
Provider IdentifiersNPI Number: 1487113775
PECOS PAC ID: 4587994652
Enrollment ID: I20220920003242

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameZachariah L Dorey-stein
Provider TypePractitioner - Pulmonary Disease
Provider IdentifiersNPI Number: 1073993267
PECOS PAC ID: 2860781481
Enrollment ID: I20220920003554

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameDang Hai Zhang
Provider TypePractitioner - Neurosurgery
Provider IdentifiersNPI Number: 1609151968
PECOS PAC ID: 4688831191
Enrollment ID: I20220921002381

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameKatherine Huang
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1306379623
PECOS PAC ID: 4880950138
Enrollment ID: I20220921002464

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameStephen Wabeti Nganga
Provider TypePractitioner - Hospitalist
Provider IdentifiersNPI Number: 1982166070
PECOS PAC ID: 7719214956
Enrollment ID: I20220924000334

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameLiah A Vega
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1518688662
PECOS PAC ID: 0840676029
Enrollment ID: I20220927000533

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameEmily Bavasi
Provider TypePractitioner - Certified Nurse Midwife (cnm)
Provider IdentifiersNPI Number: 1073189817
PECOS PAC ID: 2466838057
Enrollment ID: I20221005001846

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameSidakpal S Panaich
Provider TypePractitioner - Interventional Cardiology
Provider IdentifiersNPI Number: 1194955641
PECOS PAC ID: 8022326420
Enrollment ID: I20221012000425

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJeffrey Lee
Provider TypePractitioner - Osteopathic Manipulative Medicine
Provider IdentifiersNPI Number: 1477043370
PECOS PAC ID: 3173888443
Enrollment ID: I20221012002502

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameRakesh Khanna
Provider TypePractitioner - Urology
Provider IdentifiersNPI Number: 1326278458
PECOS PAC ID: 9133275118
Enrollment ID: I20221012002830

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameCarolyn Schwartz
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1093315970
PECOS PAC ID: 7012329675
Enrollment ID: I20221014002426

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameDeena Lee Fredregill
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1972230894
PECOS PAC ID: 6002283520
Enrollment ID: I20221111001910

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJohn Ringquist
Provider TypePractitioner - Emergency Medicine
Provider IdentifiersNPI Number: 1851369318
PECOS PAC ID: 7719142587
Enrollment ID: I20221216000314

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameLauren Elise Burton
Provider TypePractitioner - Family Practice
Provider IdentifiersNPI Number: 1124647706
PECOS PAC ID: 2365812211
Enrollment ID: I20230110002178

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameDevin Elizabeth Prior
Provider TypePractitioner - Neurology
Provider IdentifiersNPI Number: 1548657000
PECOS PAC ID: 6406154525
Enrollment ID: I20230130001224

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameKathryn Amanda Lidgard
Provider TypePractitioner - Clinical Social Worker
Provider IdentifiersNPI Number: 1003326646
PECOS PAC ID: 0042683955
Enrollment ID: I20230223001878

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameMelony Burns
Provider TypePractitioner - Clinical Social Worker
Provider IdentifiersNPI Number: 1750047510
PECOS PAC ID: 2163897141
Enrollment ID: I20230404002354

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameTrisha Leonard
Provider TypePractitioner - Clinical Social Worker
Provider IdentifiersNPI Number: 1174841571
PECOS PAC ID: 9234504291
Enrollment ID: I20230405002448

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameNegin Kourehpazan Haghighi
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1457011967
PECOS PAC ID: 5597120659
Enrollment ID: I20230426000041

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameElizabeth Tomer
Provider TypePractitioner - Clinical Social Worker
Provider IdentifiersNPI Number: 1053063842
PECOS PAC ID: 9537525936
Enrollment ID: I20230509001903

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameLynnette May Lacek
Provider TypePractitioner - Emergency Medicine
Provider IdentifiersNPI Number: 1225692643
PECOS PAC ID: 3072846625
Enrollment ID: I20230524000204

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameErrol Singh
Provider TypePractitioner - Urology
Provider IdentifiersNPI Number: 1629141577
PECOS PAC ID: 6901793942
Enrollment ID: I20230526001981

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameSamuel Brewer
Provider TypePractitioner - Emergency Medicine
Provider IdentifiersNPI Number: 1043444821
PECOS PAC ID: 2961671169
Enrollment ID: I20230623000978

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJacob Lehman
Provider TypePractitioner - Emergency Medicine
Provider IdentifiersNPI Number: 1730716465
PECOS PAC ID: 1052732112
Enrollment ID: I20230623001479

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameHarshal Athalye
Provider TypePractitioner - Emergency Medicine
Provider IdentifiersNPI Number: 1952938433
PECOS PAC ID: 8426419110
Enrollment ID: I20230727001891

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJennifer Dunlap
Provider TypePractitioner - Hospitalist
Provider IdentifiersNPI Number: 1427511997
PECOS PAC ID: 3173857018
Enrollment ID: I20230728000674

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJedediah Joseph Doane
Provider TypePractitioner - Hospitalist
Provider IdentifiersNPI Number: 1124657903
PECOS PAC ID: 1052772639
Enrollment ID: I20230728002268

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameMadeline Mercier
Provider TypePractitioner - Emergency Medicine
Provider IdentifiersNPI Number: 1669092599
PECOS PAC ID: 7113349929
Enrollment ID: I20230811000677

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameGabriela Camilla Quiroz
Provider TypePractitioner - Certified Nurse Midwife (cnm)
Provider IdentifiersNPI Number: 1285312439
PECOS PAC ID: 2769844364
Enrollment ID: I20230814003462

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NamePriyanka Malini Ravindran
Provider TypePractitioner - Emergency Medicine
Provider IdentifiersNPI Number: 1053940916
PECOS PAC ID: 2264894781
Enrollment ID: I20230816001055

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameCharles Ma
Provider TypePractitioner - Thoracic Surgery
Provider IdentifiersNPI Number: 1932543949
PECOS PAC ID: 3971808262
Enrollment ID: I20230818002923

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJamie Robinson
Provider TypePractitioner - General Surgery
Provider IdentifiersNPI Number: 1043607989
PECOS PAC ID: 5092022319
Enrollment ID: I20230822003222

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameAbubeker Hussien
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1255036125
PECOS PAC ID: 6002279908
Enrollment ID: I20230824003410

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameKyle Norder
Provider TypePractitioner - Emergency Medicine
Provider IdentifiersNPI Number: 1508421769
PECOS PAC ID: 2365805157
Enrollment ID: I20230826000038

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameMichelle Christine Julseth
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1245914506
PECOS PAC ID: 4385007970
Enrollment ID: I20230830000745

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameSally A Peterson
Provider TypePractitioner - Emergency Medicine
Provider IdentifiersNPI Number: 1093375453
PECOS PAC ID: 8527448844
Enrollment ID: I20230911002933

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameChristopher A Fong
Provider TypePractitioner - Emergency Medicine
Provider IdentifiersNPI Number: 1427685254
PECOS PAC ID: 9335561588
Enrollment ID: I20230914001544

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameSarah Maryellen Foster
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1669940987
PECOS PAC ID: 0042674541
Enrollment ID: I20230918001310

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameMehr Qureshi
Provider TypePractitioner - General Surgery
Provider IdentifiersNPI Number: 1417215955
PECOS PAC ID: 1355686015
Enrollment ID: I20230926003734

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameMosiah Wilson
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1700412525
PECOS PAC ID: 8325406929
Enrollment ID: I20230928003168

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameJacqueline Marie Hendrix
Provider TypePractitioner - Family Practice
Provider IdentifiersNPI Number: 1851915755
PECOS PAC ID: 4486077963
Enrollment ID: I20231008000194

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameAnn P Nguyen
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1639640568
PECOS PAC ID: 3375990393
Enrollment ID: I20231114000802

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameRachael A Woldstad
Provider TypePractitioner - Clinical Social Worker
Provider IdentifiersNPI Number: 1104699438
PECOS PAC ID: 1951758812
Enrollment ID: I20231114003171

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameKyle H Jasper
Provider TypePractitioner - Psychiatry
Provider IdentifiersNPI Number: 1649703075
PECOS PAC ID: 5799057410
Enrollment ID: I20231201000312

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameAudrey Rose Eichenberger
Provider TypePractitioner - Psychiatry
Provider IdentifiersNPI Number: 1275095127
PECOS PAC ID: 1254790876
Enrollment ID: I20231204000947

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameBrooke A Bucci
Provider TypePractitioner - Certified Nurse Midwife (cnm)
Provider IdentifiersNPI Number: 1346525284
PECOS PAC ID: 6406013119
Enrollment ID: I20231229002333

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameMelissa Bird
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1922612688
PECOS PAC ID: 1759732258
Enrollment ID: I20240109003453

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameAvril L Lehmann
Provider TypePractitioner - Mental Health Counselor
Provider IdentifiersNPI Number: 1710015805
PECOS PAC ID: 0840642658
Enrollment ID: I20240117002880

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameMatthew W Richey
Provider TypePractitioner - Thoracic Surgery
Provider IdentifiersNPI Number: 1104243088
PECOS PAC ID: 4486952058
Enrollment ID: I20240122004053

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameHolly Ann Brewer
Provider TypePractitioner - Mental Health Counselor
Provider IdentifiersNPI Number: 1316289549
PECOS PAC ID: 1951754886
Enrollment ID: I20240126003866

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameMorgan Michelle Newkirk
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1245882539
PECOS PAC ID: 8729431366
Enrollment ID: I20240130002391

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameYuezhou Yu
Provider TypePractitioner - Neurology
Provider IdentifiersNPI Number: 1154881209
PECOS PAC ID: 2062742034
Enrollment ID: I20240205001852

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

Provider NameSusan Janette Morrin
Provider TypePractitioner - Mental Health Counselor
Provider IdentifiersNPI Number: 1649659384
PECOS PAC ID: 9032555065
Enrollment ID: I20240312002990

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more Medical News

› Verified 7 days ago

News Archive

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

Scientists determine the origin and transmission rates of SARS-CoV-2 strains

A team of Brazilian and European scientists has determined the transmission rates and out-of-country origins of predominant SARS-CoV-2 strains currently circulating in Brazil, which harbors one of the fastest growing COVID-19 epidemics in the world.

For Mitt Romney, another voice adds to the criticisms of Mass. health plan

A top congressional Republican this morning tweaked Mitt Romney for his health care plan in Massachusetts, further illustrating the primary challenge Romney faces in his expected presidential bid. Representative Paul Ryan, a Wisconsin Republican and chairman of the House Budget Committee, criticized the Massachusetts health care plan by comparing it to President Obama's national plan.

Research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Read more News

› Verified 7 days ago

General Practice in Everett, WA

Sunrise Services, Inc.
Mental Health Clinic
Medicare: Medicare Enrolled
Practice Location: 1718 Broadway, Everett, WA 98201
Phone: 425-595-5200    Fax: 425-595-5201
Northwest Neurology & Sleep
Mental Health Clinic
Medicare: Not Enrolled in Medicare
Practice Location: 10315 19th Ave Se, Ste 112, Everett, WA 98208
Phone: 425-379-7191    Fax: 425-379-8271
Western Washington Medical Group, Inc Ps
Mental Health Clinic
Medicare: Medicare Enrolled
Practice Location: 1728 W Marine View Dr, Suite 110, Everett, WA 98201
Phone: 425-259-4041    Fax: 425-252-6642
Providence Health & Services-wa
Mental Health Clinic
Medicare: Not Enrolled in Medicare
Practice Location: 1321 Colby Ave, Everett, WA 98201
Phone: 425-261-3968    Fax: 425-261-3967
Bridgeways
Mental Health Clinic
Medicare: Not Enrolled in Medicare
Practice Location: 5801 23rd Dr W, 104, Everett, WA 98203
Phone: 425-513-8213    
Eleanor Health Professional Wa, Pllc
Mental Health Clinic
Medicare: Medicare Enrolled
Practice Location: 4310 Colby Ave Ste 201, Everett, WA 98203
Phone: 866-323-2596    
Quality Counseling And Consultation Service Llc
Mental Health Clinic
Medicare: Not Enrolled in Medicare
Practice Location: 2723 Leonard Dr, Everett, WA 98201
Phone: 206-705-9479    Fax: 206-219-0456

Find & Compare Providers Near You: Find and compare doctors, nursing homes, hospitals, and other health care providers in your area that accept Medicare. Get information like: Find a doctor or clinician that accepts Medicare near you.

Doctors and clinicians: Doctors and clinicians include doctors, clinicians and groups who are qualified to practice in many specialties. Each specialty focuses on certain parts of the body, periods of life, conditions, or primary care. The doctors, clinicians, and groups listed here typically work in an office or clinic setting. Also those who currently accept Medicare are included.

Hospitals: Find information about Medicare-certified hospitals and long-term care hospitals in your area, including Veterans Administration medical centers and military hospitals, across the country. Long-term care hospitals serve critically ill and medically complex patients who require extended hospital care.

Data provided: Information on www.medicareusa.org is built using open data sources published by Centers for Medicare & Medicaid Services (CMS) under Freedom of Information Act (FOIA).

© 2024 MedicareUsa. All rights reserved. Maintained by the Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services.